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ABSTRACT 
Nicholas A. Taylor: Balancing Pro- and Anti-Inflammatory Signals for Effective Immunotherapy 
in the Post-Hematopoietic Stem Cell Transplant and Solid Tumor Settings 
 (Under the direction of Jonathan Serody) 
 
 The immune system maintains a balance of activating and suppressive signals in order to 
promote homeostasis.  However, diseases may arise when errant signals on either side of the 
scale perturb this delicate balance.  In the work presented here, the importance of this 
equilibrium is demonstrated using two disease models, in which opposite effects are desired for 
proper treatment.  Acute graft-versus-host disease (GvHD) is the result of donor T cell activation 
to host antigen presenting cells (APCs) and target organ damage following allogeneic 
hematopoietic stem cell transplant (HSCT).  Conversely, as tumors grow, they evolve multiple 
mechanisms to evade recognition by, and suppress activation of, the immune system.  In order to 
study the differences in proper treatment of these diseases, this work focused on three projects 
related to effective immunotherapy.  
 Here, we show that donor transplanted conventional T cells (Tcons) become activated by 
host APCs 20 – 24 hours after transplant.  Endogenous Treg cells interrupt the cell-cell 
interactions between Tcon and APC and downregulate co-stimulatory molecules expressed by 
APCs, decreasing Tcon activation.  Inducible Treg cells have the same effect on Tcon activation, 
giving promise to Treg transplant as a viable therapy to prevent Tcon activation following HSCT.  
We also show that Coronin 1A, an actin-associated protein, is critical for Tcon migration from 
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secondary lymphoid tissue (SLT), where they are activated, to target organs, where they cause 
damage.  T cells deficient in Coronin 1A demonstrate delayed entry into, and impaired egress 
from, SLT following HSCT, as well as decreased NF-κB signaling.  Therefore, if preventing Tcon 
activation is not feasible, targeting the actin cytoskeleton and the NF-κB pathway may be useful 
to prevent migration and development of target organ damage. 
 Finally, we show that claudin-low breast cancers are heavily infiltrated with immune 
cells.  However, these cells are predominantly immunosuppressive Treg cells that prevent the 
development of an anti-tumor response.  Multimodality therapy that depletes Treg cells and 
prevents their function inhibits tumor growth and increases survival.  Additionally, claudin-low 
tumors express high levels of the chemokine CXCL12, and its inhibition may decrease Treg 
infiltration into the tumor.  
  
 
 
v 
 
 
 
DEDICATION 
 
To my parents, Leonard and Marianne, you made me who I am.  You instilled the appreciation of 
knowledge and the love of learning that made this all possible.   
To my brother, Phillip, and the sibling rivalry that inspired me to pursue a second doctorate.   
I win.   
To my soon-to-be wife, Rachel, your constant reminders that I would never graduate were truly 
inspiring.  
 
 
vi 
 
 
 
ACKNOWLEDGEMENTS 
 
 First thanks must go to my mentor, Dr. Jonathan Serody.  Four years is too short to learn 
everything that would make me the doctor and researcher that you are.  I hope that in the next 
two years, and the decades to come, I will continue to learn and grow with your guidance.  A 
standing ovation must be given to Shelly West, without whom no research would be possible in 
the Serody laboratory.  I cannot fathom the things you do when we are not looking, yet you still 
have time to help save me from 36 straight hours in the lab.  Thank you to Dr. Benjamin Vincent, 
who was the unspoken mentor when Dr. Serody was not there and I had no idea what I was 
doing.  To Michael Iglesia and the rest of the Perou lab, thank you for all the RNA isolated, 
arrays run, tumors given, and hands held in order to help complete this project.  To the other 
members of the Serody, Coghill, van Deventer, and Armistead labs, thank you for keeping things 
fun and reminding me to clean up after myself.  To the MD/PhD Class of 2016ish, without you I 
would have quit a long time ago.  To Dr. Rachel Kassel, I would not be in medical school or the 
MD/PhD program without your help and advice.  You got me where I am and for that I am 
eternally grateful.
 vii 
 
 
 
 
TABLE OF CONTENTS 
 
List of Figures ................................................................................................................................ ix	  
 
List of Abbreviations .................................................................................................................... xii	  
 
Chapter One: Introduction to Hematopoietic Stem Cell  
Transplantation and Tumor Immunotherapy .................................................................................. 1	  
 
1.1 Recognition of Self versus Non-Self ............................................................................ 1	  
 
1.2 Allogeneic Stem Cell Transplant .................................................................................. 5	  
 
1.3 Mouse Models of Acute Graft-versus-Host Disease .................................................... 9	  
 
1.4 Tumor Immunotherapy ............................................................................................... 11	  
 
1.5 Immunosuppressive Tumor Microenvironment ......................................................... 13	  
 
1.6 Methods of Immunotherapy ........................................................................................ 18	  
 
1.7 Intrinsic Breast Cancer Subtypes ................................................................................ 23	  
 
1.8 Genetically Engineered Mouse Models ...................................................................... 24	  
 
1.9 Dissertation Aims ........................................................................................................ 25	  
 
REFERENCES ................................................................................................................. 27	  
 
Chapter Two: Intravital Imaging of Donor Allogeneic Effector  
and Regulatory T Cells with Host Dendritic Cells During GvHD ............................................... 37	  
 
2.1 Introduction ................................................................................................................. 37	  
 
2.2 Methods....................................................................................................................... 40	  
 
2.3 Results ......................................................................................................................... 41	  
 
 viii 
2.4 Discussion ................................................................................................................... 47	  
 
2.5 Supplementary Methods ............................................................................................. 66	  
 
REFERENCES ................................................................................................................. 76	  
 
Chapter Three: Altered T-Cell entry and egress in the absence  
of Coronin 1A attenuates murine acute graft versus host disease ................................................ 80	  
 
3.1 Introduction ................................................................................................................. 80	  
 
3.2 Materials and Methods ................................................................................................ 82	  
 
3.3 Results ......................................................................................................................... 87	  
 
3.4 Discussion ................................................................................................................... 92	  
 
REFERENCES ............................................................................................................... 108	  
 
Chapter Four: Mutlimodality treatment targeting regulatory T cell  
number and function diminishes tumor growth of triple negative  
claudin-low breast cancer ........................................................................................................... 112 
 
4.1 Introduction ............................................................................................................... 112	  
 
4.2 Methods..................................................................................................................... 115	  
 
4.3 Results ....................................................................................................................... 121	  
 
4.4 Discussion ................................................................................................................. 128	  
 
REFERENCES ............................................................................................................... 148	  
 
Chapter Five: Discussion ............................................................................................................ 151	  
 
5.1 Cell location .............................................................................................................. 151	  
 
5.2 Cell type .................................................................................................................... 156	  
 
5.3 Concluding Remarks ................................................................................................. 160	  
 
REFERENCES ............................................................................................................... 161	  
 ix 
LIST OF FIGURES 
 
Figure 2.1: Donor T cells show decreased velocity, low  
displacement ratios, and early engagement with dendritic cells in  
lymph nodes 2 hours after transplant............................................................................................ 52 
 
Figure 2.2: The kinetics of T cell-DC interaction is similar  
in mice after chemotherapy or in BALB/c to CD11c-YFP mice.................................................. 54 
 
Figure 2.3: eTregs show stable interactions with host DCs and  
interfere with the interaction between donor T cells and  
DCs in the lymph nodes................................................................................................................ 56 
 
Figure 2.4: Inducible Tregs interfere with the interactions  
between donor T cells and host DCs comparable to eTregs........................................................... 58 
 
Figure 2.5: IL-10 is required for Treg-mediated disruption  
of Tcon-DC interaction................................................................................................................... 60 
 
Figure 2.6: Tregs down-regulate CD86 and CD54 on  
dendritic cells................................................................................................................................ 62 
 
Figure 2.7. Tregs promote DC death............................................................................................... 64 
 
Supplementary Figure 2.S1: Donor T cells display stable  
contacts with DCs from 2 hours post-transplant........................................................................... 70 
 
Supplementary Figure 2.S2: Suppression of T cell proliferation  
by endogenous Tregs and inducible Tregs........................................................................................ 71 
 
Supplementary Figure 2.S3: eTreg and iTreg disrupt Tcon-DC interaction  
while their own interactions with DC are not affected by Tcon..................................................... 72 
 
Supplementary Figure 2.S4: iTregs also express FasL................................................................... 74 
 
Supplementary Figure 2.S5: DC:T cell interactions within the  
lymph node following allogeneic transplantation......................................................................... 75 
 
Figure 3.1: Attenuated GvHD in the absence of Coro 1A............................................................ 96 
 
Figure 3.2: Histopathology of B6D2 recipients after transplantation  
of Coro 1A-/- or WT Tcon cells....................................................................................................... 97 
 
 
 x 
Figure 3.3: Delayed entry and impaired egress in secondary  
lymphoid organs by Coro 1A-/- Tcon cells..................................................................................... 98 
 
Figure 3.4: Decreased receptor expression and impaired  
chemotaxis in the absence of Coro 1A........................................................................................ 100 
 
Figure 3.5: Decreased activation of NF-κB in Coro 1A-/- Tcon cells........................................... 101 
 
Figure 3.6: GvL response using Coro 1A-/- Tcon cells................................................................ 102 
 
Supplementary Figure 3.S1: Cytokine production, proliferation,  
and chemotaxis of Coro 1A-/- T-cells........................................................................................... 104 
 
Supplementary Figure 3.S2: Decreased proliferation in vivo  
in the absence of Coro 1A............................................................................................................ 105 
 
Supplementary Figure 3.S3: p38 expression in Coro 1A-/- T-cells.............................................. 107 
 
Figure 4.1: Human tumors exhibit differential immune  
gene expression............................................................................................................................ 132 
 
Figure 4.2: T11 (Claudin-low) tumors recruit elevated numbers  
of immune cells to the tumor site................................................................................................. 134 
 
Figure 4.3: FoxP3+ cells from T11 tumor-bearing mice are  
functionally suppressive............................................................................................................... 136 
 
Figure 4.4: Treg depletion delays tumor growth in the absence  
of adoptive transfer...................................................................................................................... 137 
 
Figure 4.5: Multimodality therapy combining Cy with anti-PD-1  
and anti-CTLA-4 immune checkpoint inhibition significantly  
delays tumor growth.................................................................................................................... 139 
 
Figure 4.6: T11 tumors express high levels of CXCL12............................................................. 140 
 
Figure 4.7: CXCL12-CXCR4 pathway is important for Treg  
infiltration into claudin-low tumors............................................................................................. 141 
 
Supplementary Table 4.1: Intrinsic Immune Genes.................................................................... 143 
 
Supplementary Figure 4.S1: Tumors derived from T11 cell line  
result in true claudin-low tumors................................................................................................. 144 
 
Supplementary Figure 4.S2: Representative FACS analysis diagram......................................... 145 
 
 xi 
Supplementary Figure 4.S3: PD-1 and CTLA-4 inhibition  
does not increase survival in T11 tumor bearing mice................................................................ 146 
 
Supplementary Figure 4.S4: Anti-tumor response following  
combination therapy..................................................................................................................... 147 
 
 
 
 
 
 xii 
LIST OF ABBREVIATIONS 
 
APC Antigen Presenting Cell 
BCR B-Cell Receptor 
BM Bone Marrow 
BMT Bone Marrow Transplant 
CAR Chimeric Antigen Receptor 
CCL C-C Chemokine Ligand 
CCR C-C Chemokine Receptor 
CD Cluster of Differentiation 
CFSE Carboxyfluorescein Succinimidyl Ester 
Coro 1A Coronin 1A 
COX Cyclooxygenase  
CRP C-Reactive Protein 
CTLA4 Cytotoxic T Lymphocyte Antigen 
CXCL C-X-C Chemokine Ligand 
CXCR C-X-C Chemokine Receptor 
Cy Cyclophosphamide 
DAMP Danger Associated Molecular Patters 
DC Dendritic Cell 
DT Diphtheria Toxin 
DTR Diphtheria Toxin Receptor 
EGFP Enhanced Green Fluorescent Protein 
 xiii 
ER Estrogen Receptor 
eTreg Endogenous Treg 
FACS Fluorescence Activated Cell Sorting 
FasL Fas Ligand 
FIR FoxP3-mRFP mouse 
FOXP3 Forkhead box P3 
GEMM Genetically Engineered Mouse Model 
GFP Green Fluorescent Protein 
GM-CSF Granulocyte/Macrophage Colony Stimulating Factor 
GvHD Graft-versus-Host Disease 
GvL Graft-versus-Leukemia 
HER2 Human Epidermal Growth Factor Receptor 2 
HSCT Hematopoietic Stem Cell Transplant 
IFN Interferon 
IL Interleukin 
ILN Inguinal Lymph Node 
iNOS Inducible Nitric Oxide Synthase 
IPEX Immunodysregulation Polyendocrinopathy Enteropathy X-Linked 
iTreg Inducible Treg 
LN Lymph Node 
LPS Lipopolysaccharide 
MBL Mannose Binding Lectin 
MDSC Myeloid-Derived Suppressor Cell 
 xiv 
MHC Major Histocompatibility Complex 
miHA Minor Histocompatibility Antigen 
MLN Mesenteric Lymph Node 
MMTV Mouse Mammary Tumor Virus 
MPLSM Multiphoton Laser Scanning Microscopy 
mRFP Multimeric Red Fluorescent Protein 
NFAT Nuclear Factor and Activator of Transcription 
NF-κB Nuclear Factor kappa-Light-Chain Enhancer of Activated B Cells 
NK Natural Killer 
NLR Leucine Rich Nucleotide-Binding Oligomizerization Domain Like 
 Receptors 
 
NO Nitric Oxide 
NOX2 NADPH Oxidase 2 
NRP1 Neuropilin 1 
PAMP Pathogen Associated Molecular Patterns 
PD Programmed Death 
PD-L Programmed Death Ligand 
PI3K Phosphatidyl Inositol 3 Kinase 
PR Progesterone Receptor 
ROS Reactive Oxygen Species 
S100A9 S100 Calcium Binding Protein A9 
S1P Sphingosine 1 Phosphate 
S1Pr1 Sphingosine 1 Phosphate Receptor 1 
SCF Stem Cell Factor 
 xv 
SCT Stem Cell Transplant 
Sema-3A Semaphorin 3A 
SLT Secondary Lymphoid Tissue 
STAT Signal Transducer and Activator of Transcription 
TAA Tumor Associated Antigen 
TCD T-Cell Depleted Bone Marrow 
Tcon Conventional T Cell 
TCR T-Cell Receptor 
TGF Transforming Growth Factor 
TLR Toll-like Receptor 
TNF Tumor Necrosis Factor 
Treg Regulatory T Cell 
VEGF Vascular Endothelial Growth Factor 
VEE Venezuelan Equine Encephalitis Virus 
VRP Viral Replicon Particle 
WT Wild Type 
YFP Yellow Fluorescent Protein 
 
 
 1 
 
 
 
CHAPTER ONE 
INTRODUCTION TO HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 
TUMOR IMMUNOTHERAPY 
 
1.1 Recognition of Self versus Non-Self 
 The primary role of the immune system is to recognize and eliminate foreign pathogens.  
However, for this to occur, the immune system must be able to distinguish between self and non-
self, ignoring the former, and eradicating the latter.  The ability to specifically activate an 
immune response against foreign pathogens while ignoring host tissue is dependent on both the 
innate and adaptive immune system.  The innate immune system provides host defense by 
monitoring the presence of foreign microbes in a non-specific manner, using germline encoded 
antigen receptors.  Meanwhile, the adaptive immune system uses antigen-specific receptors that 
are generated de novo in each cell, endowing each cell with a unique receptor unlike any of its 
contemporaries.  While the innate immune system presents antigens from sources that are both 
self and non-self, it is the specificity of the adaptive immune system that protects host tissues 
from unnecessary damage. 
 
Innate Immune System 
 The innate immune system is composed of cells that recognize foreign pathogens using 
antigen receptors that are genetically fixed [1].  These receptors recognize Pathogen-associated 
Molecular Patterns (PAMPs) or Danger-associated Molecular Patterns (DAMPs) that are the 
“danger signals” first described by Matzinger [2].  PAMPs are evolutionarily conserved pattern 
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motifs present on pathogens that are essential for microbial survival.  DAMPs are signs of 
stressed or injured host cells.  Different Pattern Recognition Receptors (PRRs) that bind PAMPs 
and DAMPs are expressed both in the cytoplasm and on the cell surface by many innate cells, 
including endothelial cells, dendritic cells, macrophages, and neutrophils [1].   
 Toll-like Receptor (TLR) 4, one such PRR, recognizes the lipopolysaccharide (LPS) 
antigen expressed by gram-negative bacteria, a critical component of the cell wall [3].  There are 
numerous such TLRs, each of which recognizes different molecular patterns associated with 
different pathogens (gram-positive bacteria, RNA viruses, DNA viruses, etc.).  Additionally, 
there are other pattern recognition receptors, including the leucine rich nucleotide-binding 
oligomerization domain-like receptors (NLRs), mannose-binding lectin (MBL), and C-reactive 
protein (CRP) [1, 3].  Engagement of the PRR begins a signaling cascade within the cell that 
leads to antigen processing, transcription factor activation, production of proinflammatory 
cytokines, and increased expression of co-stimulatory molecules important for activation of the 
adaptive immune system. 
 Natural killer (NK) cells, another member of the innate immune system, use the opposite 
method to detect foreign pathogens.  NKs are similar to T lymphocytes, discussed below, but 
they do not express somatically rearranged antigen receptors and possess the ability to kill target 
cells without the need for co-stimulation.  Instead of expressing receptors for the pathogens 
themselves, NK cells express inhibitory receptors that are specific for major histocompatibility 
complex (MHC) molecules expressed on host cells [4].  Loss of MHC expression from the 
surface of a host cell, which may occur during infection or cellular stress, results in a loss of 
inhibition and potential activation of the NK cell.  NK cell activation is then dependent on the 
magnitude of activating signals.  Once example of an activating receptor is NK-expressed 
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NKG2D, whose ligands MICA or MICB are upregulated on target cells as a result of cellular 
stress [4, 5].  Upon activation, the NK cell may kill the target cell and produce cytokines that 
activate other parts of the innate or the adaptive immune system.  
 
Adaptive Immune System 
 The adaptive immune system consists of both T and B lymphocytes, which possess the 
unique ability to undergo gene rearrangement at the genetic level to produce a near-infinite 
number of antigen-specific T cell receptors (TCRs) or B cell receptors (BCRs) [1, 6, 7].  The 
activation of T lymphocytes is regulated by antigen presenting cells (APCs) of the innate 
immune system.  APCs, such as macrophages and dendritic cells (DCs), process antigens and 
display them on the cell surface, bound to MHC class I or class II molecules.  Effective 
activation of lymphocytes is dependent upon sufficient co-stimulation by the APC, which occurs 
following APC recognition of PAMPs or DAMPs.  These requirements are known as the two-
signal hypothesis: antigen-specific receptor recognition coupled with APC-dependent co-
stimulation only during times of pathogen invasion or inflammation [8].  Coupling these 
processes prevents false-positive activation and helps ensure that the adaptive immune response 
is directed to foreign pathogens, not uninfected host tissues.  Following activation, B 
lymphocytes differentiate into plasma cells that produce antibody (B cells).  Activated T cells 
can provide co-stimulation through cell-surface ligands and cytokine production (CD4+ helper T 
cells) or mediate direct killing of infected cells (CD8+ cytotoxic T cells).  Finally, a hallmark of 
the adaptive immune response is the differentiation of memory cells that respond quickly to their 
cognate antigen during a secondary response, without the need for the protracted activation steps 
required in the primary response [1]. 
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 There are two other methods that further protect host tissue from unnecessary attack by 
the adaptive immune system: central and peripheral tolerance.  Central tolerance is mediated by 
negative selection, or the active cell death that occurs during lymphocyte development when the 
newly recombined antigen receptor recognizes self-antigen [7, 9, 10].  Although central deletion 
does not occur with 100% fidelity, self-reactive cells that escape to the periphery are silenced 
through mechanisms of peripheral tolerance.  These mechanisms include differentiation of 
immunosuppressive (FoxP3)-expressing regulatory T cells (Treg), anergy, ignorance, or cell death 
[9, 11, 12].  
 
Key to Effective Immune Response: Balance of Activation and Suppression 
 The primary response to a foreign pathogen requires rapid and coordinated execution of 
the steps discussed above: (1) innate cell activation and presentation of antigen, (2) antigen-
specific activation of the adaptive immune system, and (3) antigen-specific killing of target cells.  
However, when the pathogen has been cleared, the immune system must rein in its efforts and 
return to its basal resting state.  This waning of the immune response is known as the contraction 
phase, and it is mediated by pro-apoptotic signals resulting from a decline in antigen and 
proinflammatory cytokines, as well as an increase in regulatory tolerance mechanisms [1]. 
 At all times, the immune system is bombarded with foreign antigen.  Whether this assault 
results in an immune response is dependent on the balance of pro-inflammatory immuno-
activation signals and anti-inflammatory immuno-suppressive signals.  The relative strength of 
these two signals determines whether the scale is tipped towards activation or suppression.  Like 
all biologic systems, too much weight on either side of the scale can result in disease.  During 
times of too much immune activation and insufficient immunosuppression, diseases of 
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autoimmunity may arise.  However, too much immunosuppression and insufficient activation 
may result in inaction to an ongoing disease process.   
 The importance of both activation and suppression of the immune system can be 
understood by studying two disease states that lie on both sides of the scale: graft-versus-host 
disease (GvHD) and tumor immune evasion.  Symptoms of GvHD result from rampant immune 
activation and targeted cell killing of host tissues [13, 14].  Current treatments of GvHD revolve 
around decreasing immune cell activation and increasing immunosuppressive signals to dampen 
the immune response.  Conversely, as tumors grow, they evolve multiple mechanisms to promote 
immunosuppression and escape detection by the immune system [15, 16].  Therefore, immune-
mediated methods to treat tumor growth involve decreasing immunosuppressive signals and 
promoting immune cell activation against the tumor.  How these diseases are two sides of the 
same coin are discussed below. 
 
1.2 Allogeneic Stem Cell Transplant 
Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred treatment 
method of patients with high-risk hematologic malignancies and congenital or acquired bone 
marrow failure syndromes [17].  Over 50 thousand transplants are performed each year, and the 
number is rising [18].  Unfortunately, this life-saving treatment is underutilized in non-life-
threatening disorders due to the occurrence of acute and chronic graft-versus-host disease.   
 
Graft-versus-Host Disease 
 Acute GvHD is the result of donor T cell activation, due to disparities between minor and 
major histocompatibility antigens expressed by host APCs [13].  Activated host APCs, resulting 
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from underlying disease or secondary to the conditioning regimen, produce proinflammatory 
cytokines and upregulate co-stimulatory molecule expression [19].  Widespread donor T cell 
activation results in the destruction of host target organs, primarily the skin (81% of patients), 
gastrointestinal tract (54% of patients), and liver (50% of patients) [20, 21].  Skin is the most 
commonly affected organ, usually resulting in a diffuse maculopapular rash that includes the 
palms of the hands and the soles of the feet.  The rash may be pruritic, and in extreme cases, 
blister and ulcerate [20, 21].  Gastrointestinal involvement usually presents with secretory 
diarrhea.  Bleeding, which may occur as a result of mucosal ulceration, portends a poor 
prognosis [20].  Therefore, the importance of this life-saving treatment necessitates that we be 
able to curb such drastic side effects.  
 
Graft-versus-Leukemia 
 The same processes that mediate GvHD are actually essential to the success of the 
treatment.  Initial attempts to prevent acute GvHD involved depletion of donor T cells from the 
stem cell preparation [22, 23].  However, myeloablative therapy is rarely complete, and some 
residual host T cells may be to mediate an immune response to the transplanted MHC-
mismatched tissue and rejection of the graft.  When donor T cells are included in the stem cell 
infusion, the same allo-response process that mediates graft rejection results in donor T cell-
mediated killing of residual host immune cells and decreases the probability of graft rejection.  
Similarly, this allo-response results in killing of residual host leukemic cells and decreases the 
probability of tumor relapse [24].  This process, known as the graft-versus-leukemia (GvL) 
effect, is a critical component of effective treatment by allogeneic HSCT.  Therefore, the  
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possibility of acute GvHD is a necessary risk of this life-saving treatment, and the prevention or 
treatment of GvHD must be balanced with the possibility of increased graft rejection or reduced 
GvL effect. 
 
Clinical and Theoretical Treatments of GvHD 
 Current clinical treatments of GvHD revolve around global immune suppression to 
reduce the severity of symptoms [25].  The standard of care to treat GvHD includes 
glucocorticoids or calcineurin inhibitors.  Glucocorticoids, such as methylprednisolone, produce 
their suppressive effect through the repression of proinflammatory genes, decreases in cell 
migration, and T cell cytolysis [26].  The calcineurin inhibitor cyclosporine inhibits transcription 
of nuclear factor of activated T cells (NFAT)-dependent genes, including the cytokine 
interleukin-2 (IL-2), which is important for T cell proliferation [27, 28].   
 Current theoretical methods take a more targeted approach to treating acute GvHD.  One 
such approach attempts to use the immunosuppressive effect of regulatory T cells (Treg) to 
decrease effector T cell activation and function.  Studies have shown that an increased dose of 
Treg cells with the stem cell inoculum results in decreased severity of GvHD [29-32].  A second 
approach aims to inhibit the migration of effector T cells, either from the infusion site into 
secondary lymphoid tissue (SLT), where they become activated, or from SLT to target organs, 
where they cause damage.  One example of the former is the use of chemokine receptor 
inhibitors to prevent T cell migration into secondary lymphoid tissue.  Indeed, work by our 
laboratory has shown that inhibition of the C-C chemokine receptor CCR7 prevents GvHD [33].  
An example of the latter aims to prevent the actin cytoskeletal rearrangements necessary for T 
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cell movement into SLT as well as the target organ.  One such class of targets is the actin 
interacting family of proteins known as Coronins [34].   
 
Coronins 
 The actin cytoskeleton is required for cell motility, migration, and trafficking.  Existing in 
either monomeric actin subunits (G-actin) or filamentous oligomers (F-actin), the homeostatic 
rearrangement and recycling of these two forms allows cells to make the cytoskeleton alterations 
necessary for movement [35].  The Coronin family of proteins was shown to be important for 
cytoskeletal rearrangement following the discovery of, and its interaction with, the Arp2/3 
complex [36, 37].  The primary role of Arp2/3 complex was previously shown to promote 
polymerization of monomeric G-actin subunits into the F-actin form [38]. 
 The Coronin family of proteins is divided into Type I and Type II classes [39].  Type I 
Coronins consist of Coronin 1A, Coronin 1B, and Coronin 1C.  Coronin 1A is expressed 
primarily in hematopoietic cells.  Coronins 1B and 1C exhibit more ubiquitous expression, but 
both proteins have been implicated in migration and cytokinesis [40-43].  Defects in Coronin 1A, 
the most extensively studied protein in the family, has been implicated in patients with Severe 
Combined Immunodeficiency and mouse models of Systemic Lupus Erythematosus [44, 45].  In 
both cases, defects in T cell development and migration during thymic selection resulted in 
decreased T cell numbers in the periphery.  Type II Coronins consist of Coronin 2A and Coronin 
2B [39].  Coronin 2A is expressed in the uterus, ovaries, testes, and brain.  Coronin 2B is 
primarily expressed in the brain.  However, the function of Type II Coronins has yet to be 
determined.  A Type III class has been proposed, but it is limited to one gene, Coronin 7.  This 
gene is ubiquitously expressed, but at lower levels than the other family members [39]. 
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1.3 Mouse Models of Acute Graft-versus-Host Disease 
 Mouse models provide a robust system in which to study the pathogenesis of GvHD.  
These models take advantage of the inbred nature of mouse strains to parse out the relative 
importance of individual variables.  These models have shown that the degree of MHC mismatch 
is directly proportional to severity of disease, as well as the importance of donor T cell dose and 
their subsets on severity of disease [20, 30, 46].  Following myeloablative or non-myeloablative 
conditioning, recipient mice undergo hematopoietic reconstitution by T cell depleted bone 
marrow, without the inclusion of contaminating effector T cells.  In this way, the number of 
transplanted T cells that mediate disease can be standardized and studied systematically.  Our 
laboratory uses mouse models of acute GvHD to study the relative importance of MHC 
mismatch disparity, specific T cell subsets, and different knockout phenotypes.  While many 
models have been used, our laboratory focuses on three well-established models to help inform 
our clinical knowledge: complete major mismatch, haploidentical major mismatch, and minor 
histocompatibility antigen (miHA) mismatch.   
 
Complete Major Mismatch: C57BL/6 into BALB/c 
 Complete MHC mismatch transplants are not performed clinically due to the high 
mortality and complications associated with this treatment.  While this model is not clinically 
relevant, it continues to provide important information about the contribution of specific T cell 
populations to GvHD pathogenesis and potential treatment options in a stringent model setting.   
  In the C57BL/6 (B6) into BALB/c model, lethally irradiated BALB/c (H-2d) recipients 
are transplanted with B6 (H-2b) T cell depleted (TCD) bone marrow and T cells by intravenous 
tail vein injection.  Depending on irradiation and T cell doses, symptoms of GvHD begin 
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between day 10 and day 30 post-transplant [14].  Symptoms are evaluated using a clinical 
grading system to assess the degree of weight loss, fur texture, posture, skin disease, and activity 
level [47].  Mortality is assessed when the clinical GvHD score reaches a predetermined level. 
 
Haploidentical Major Mismatch: CD57BL/6 into B6D2 
 Only a small percentage of patients undergoing HSCT can receive a complete MHC 
matched transplant.  The use of bone marrow registries and donor programs has increased the 
probability of finding a donor, but finding a complete match remains a statistical improbability.  
Not only are patients of minority backgrounds underrepresented in these registries, but greater 
diversity at the MHC loci further decreases the probability of finding a complete match [48, 49].  
In the absence of an MHC-matched sibling, some degree of mismatch at the MHC loci is 
tolerated during emergent cases.  Therefore, the clinical use of partial-mismatch transplants is 
increasing in frequency [48].   
 In the haploidentical model, transplant recipients are the F1 generation of a cross between 
the B6 and DBA/2 (H-2d) strains, known as B6D2 (H-2b x d).  B6D2 recipients are lethally 
irradiated and transplanted with B6 T cell depleted bone marrow and T cells.  Transplanted 
recipients are graded using the same approach described above, and usually succumb to disease 
by day 30 post-transplantation [14]. 
 
Minor Mismatch: C57BL/6 into BALB.B 
 Minor mismatch transplants are the most clinically desired form of HSCT transplant [48].  
Stem cell donation by an MHC-matched sibling decreases the likelihood of a histocompatibility 
mismatch beyond the 10 alleles that are normally evaluated before transplant [48].  In this 
 11 
setting, GvHD is not due to differences in MHC allelic expression.  Instead, disease is due to 
differences in protein sequence, processing, and presentation between individuals [13].  While 
these models exhibit less severe symptoms, recipient mice still succumb to disease.  In this 
model, BALB.B (H-2b) recipients are lethally irradiated and transplanted with B6 T cell depleted 
bone marrow and T cells [14].  Again, severity of disease is evaluated using the clinical scoring 
system described above.  
 
1.4 Tumor Immunotherapy 
 The field of tumor immunotherapy arguably began when William Coley, a bone surgeon 
at what is now Memorial Sloan-Kettering Cancer Center in New York, read the case of a patient 
whose recurrent sarcoma only regressed following a severe infection with Streptococcus 
pyogenes [50-52].  In an attempt to replicate the finding, Coley attempted to infect a series of 
patients with live cultures of S. pyogenes.  Unfortunately, patient outcomes varied from no 
infection, to tumor regression, to patient death from infection.  In order to avoid this 
unpredictability, Coley made an inactivated vaccine containing S. pyogenes and Serratia 
marcescens.  With this cocktail, known as “Coley’s toxin,” he went on to cure his next patient of 
inoperable, metastatic sarcoma [53].  The success of this treatment was not limited to sarcomas 
either, with carcinoma five-year survival rates similar to that of sarcomas [52].   
 Coley’s method never gained wide medical acceptance for a variety of reasons.  First, 
there was no standardized preparation of Coley’s toxin, with both physician-to-physician and lot-
to-lot variability.  Second, no placebo-controlled trial was ever conducted, preventing definitive 
evidence of its efficacy.  Third, sterile technique during surgery and the use of post-surgery 
antibiotics were reducing the number of cases of postoperative infection.  Fourth, the use of 
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radiation therapy was becoming the established method of cancer treatment.  Finally, the 
chemotherapeutic effects of the nitrogen alkylating mustards used in World War I were gaining 
acceptance [50].  All of these factors shifted focus away from the purposeful infection of patients 
to the new methods of radiation treatment and chemotherapy. 
 The use of the immune system in cancer treatment underwent a revival in the 1960’s with 
the proposal of the “immunological surveillance” hypothesis [51, 54].  This hypothesis suggested 
that lymphocytes could eliminate transformed cells through the recognition of tumor-associated 
antigens (TAAs), or antigens not associated with healthy host tissue.  However, this hypothesis 
was founded on experiments studying chemically-induced sarcomas, which may express neo-
antigens not present in a spontaneous, host-derived tumor.  This hypothesis fell further out of 
favor with the belief that all lymphocytes recognizing self-antigen were negatively selected and 
centrally deleted.  Immunosurveillance and immunotherapy experienced a second revival with 
the characterization of a number of TAAs that occur in both mice and humans [51, 55-57].  
These antigens may be expressed due to incorrect genetic processing, including intronic 
transcription, antisense transcription, or post-translational modification, or due to preferential 
overexpression by tumor cells [57].  With the discovery that not all self-reactive lymphocytes are 
centrally deleted, the search for TAAs that could mediate tumor clearance began in earnest [2, 
58, 59].  Increased understanding of immune checkpoint inhibition further propelled our ability 
to elicit robust immune responses to TAAs [60].  Unfortunately, this has not always translated 
into effective anti-tumor therapy. 
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1.5 Immunosuppressive Tumor Microenvironment 
 Even with the discovery of selective and specific TAAs, the ability of the immune system 
to therapeutically induce tumor regression has remained disappointing [15].  Because 
spontaneous tumors arise from host tissue, central and peripheral tolerance mechanisms work to 
prevent an anti-tumor immune response.  In addition, tumors evolve active mechanisms of 
immunosuppression during their growth to further inhibit the anti-tumor response.  Two such 
mechanisms are the recruitment and expansion at the tumor site of myeloid-derived suppressor 
cells and regulatory T cells. 
 
Myeloid-derived Suppressor Cells 
 Myeloid-derived suppressor cells (MDSCs) are one of the leading mediators of tumor-
induced immunosuppression [61].  Under normal conditions, immature myeloid cells 
differentiate into mature myeloid cells, including granulocytes, macrophages, and DCs [62].  
Under conditions of chronic stress or inflammation, like that which occurs with increasing tumor 
burden, these immature myeloid cells are prevented from differentiating and maturing.  MDSCs 
in the mouse are characterized by co-expression of the myeloid lineage differentiation markers 
CD11b and Gr1 [63].  Although cells of this phenotype make up a substantial portion of bone 
marrow cells, a healthy, naïve mouse contains less than 2.5% CD11b+Gr1+ cells in the spleen.  
Tumor-bearing mice, however, can see this population rise to nearly 50% of all cells in the 
spleen.  Human cancer patients exhibit a similar expansion of their MDSC population 
(CD11b+CD14-CD33+) in the periphery [61, 64].  
 Multiple pathways contribute to MDSC expansion, including cyclooxygenase 2 (COX2), 
prostaglandins, stem-cell factor (SCF), granulocyte/macrophage colony stimulating factor (GM-
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CSF), IL-6, and vascular endothelial growth factor (VEGF) [62, 65-67].  Interestingly, most of 
these signaling cascades converge on the signal transducer and activator of transcription 3 
(STAT3) transcription factor [67-69].   STAT3 then drives MDSC expansion through activation 
of genes such as cyclin D1 and Myc.  In addition, STAT3-dependent expression of S100 
calcium-binding protein A9 (S100A9) prevents MDSC differentiation into mature myeloid cells 
[70]. 
 It was recently discovered that the Gr1 antibody used to describe murine MDSCs actually 
binds two epitopes, both Ly-6G and Ly-6C [63].  The use of antibodies that can distinguish these 
epitopes allows murine MDSCs to be further divided into two functionally distinct subsets: 
CD11b+Ly6GhiLy6C- “granulocytic” MDSCs and CD11b+Ly6G-Ly6C+ “monocytic” MDSCs.  
Although both populations increase in the tumor setting, the Ly6GhiLy6C- granulocytic 
population was found to preferentially expand in tumor-bearing mice [63].  Monocytic MDSCs 
were also the only subset able to differentiate into mature DCs and macrophages in vitro [63].  
These findings suggest that granulocytic MDSCs are the more relevant subset to be treated in an 
attempt to overcome MDSC-mediated, tumor-induced immunosuppression. 
 The granulocytic and monocytic subsets were also found to mediate suppression through 
common and subset-specific mechanisms [62].  One such mechanism common to all MDSCs is 
the production of high levels of Arginase 1.  This enzyme converts the amino acid L-arginine 
into urea and L-ornithine [62].  Depletion of L-arginine from the tumor microenvironment 
inhibits T cell proliferation.  Monocytic MDSCs also express inducible Nitric Oxide Synthase 
(iNOS), which further catabolizes L-arginine from the tumor microenvironment.  In addition to 
the decrease of L-arginine available for T cell metabolism, the iNOS reaction generates nitric 
oxide (NO) to further suppress T cell function and induce T cell apoptosis.  Granulocytic 
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MDSCs express high levels of NADPH oxidase 2 (NOX2) in order to produce large amounts of 
reactive oxygen species (ROS), predominantly superoxide anion [71].  Unsurprisingly, several 
tumor-derived cytokines can induce ROS production, including TGF-β, IL-6, IL-10, and GM-
CSF [62].  Consistent with the preferential expansion of granulocytic MDSCs in tumor-bearing 
mice and human patients, ROS is one of the main mediators of tumor-induced, MDSC-mediated 
immunosuppression [72].  However, these two subsets should not be considered to act 
independently.  Peroxynitrite, the product of the reaction of NO and superoxide anion, is another 
powerful oxidant.  Peroxynitrite-mediated nitration and nitrosylation of the T cell receptor and 
CD8 co-receptor alters peptide binding and induces antigen-specific T cell unresponsiveness [62, 
73].  
 
Regulatory T Cells 
 The existence of a suppressive T cell population was first identified in the early 1970s, 
and their ability to suppress anti-tumor immunity was demonstrated shortly thereafter [74-76].  
Unfortunately, interest in this population waned with increasing dispute over their classification 
as a unique subset.  The decline in interest in this population was due to several reasons, 
including the belief that negative selection depleted all self-reactive T cells, as well as the lack of 
a definitive identification marker for the suppressive subset.  Although these cells remained a 
point of contention for decades, Sakaguchi, et al., proved the existence of Treg cells and identified 
the alpha chain of the IL-2 receptor (CD25) as a phenotypic marker for this population [77].  
Several years later, phenotypic similarities between Scurfy mice and human patients with the 
severe autoimmune disease immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome led to the identification of the Forkhead box P3 (FoxP3) transcription factor as 
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both necessary and sufficient for the differentiation of Treg cells [78-80].  It is now widely 
accepted that during thymic development, T cells that bind self-antigen with insufficient avidity 
to be centrally deleted can induce expression of FoxP3 and differentiate into natural or 
endogenous Treg cells [81, 82]. 
 Regulatory T cells mediate immunosuppression through a variety of mechanisms, 
including cytokine-mediated and cell-cell contact-mediated suppression.  Constitutive expression 
of CD25 allows Treg cells to act as scavengers of IL-2, decreasing the pool of cytokine available 
to activate effector T cells and promote their proliferation [83].  Treg cells also produce the 
immunosuppressive cytokines IL-10 and TGF-β [11].  These cytokines not only inhibit APC 
function, but are also the inducers and subsequent suppressive mediators of the inducible Treg 
(iTreg) subset.  Inducible Treg cells do not express FoxP3 as a result of thymic development, but 
begin to express it in the periphery, as a result of the combination of TCR engagement with 
insufficient co-stimulation.  Other factors can induce iTreg differentiation, including IL-10 and 
TGF-β [11].  
 Cell-cell contact Treg-mediated suppression can induce target effector cell death or render 
the target cell unresponsive.  The factors granzyme B and perforin, once thought to be reserved 
to the NK and the cytotoxic CD8+ T cell subsets, are used by Treg cells to induce APC and 
effector T cell death [11, 84, 85].  In addition, Treg cells express multiple cell surface proteins to 
suppress effector T cell function.   
 
Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) 
 Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) is a member of the CD28 family of 
receptors [86, 87].  Naive T cells require co-stimulation through T cell-expressed CD28 binding 
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of CD80/CD86 on APCs for effective activation.  CTLA-4 shares sequence homology to CD28 
and contains the same hexapeptide MYPPPY important for ligand binding [86].  However, 
CTLA-4 has been shown to bind CD80/CD86 with 50 – 2000-fold stronger affinity than CD28 
[87].  CTLA-4 expression is induced following TCR engagement, where it can then outcompete 
CD28 for ligand binding and inhibit T cell activation.  TCR signaling, combined with suboptimal 
co-stimulation, secondary to high CTLA-4 signaling, can induce iTreg differentiation from naïve 
T cells [82].  CTLA-4 can suppress T cell activation by recruiting phosphatases to the TCR 
cytoplasmic domain or by stripping CD80/CD86 from the surface of APCs.  CTLA-4 is also 
critical for Treg cell function, on which it is constitutively expressed [87, 88].  CTLA-4-deficient 
Treg cells exhibit decreased suppressive activity, and decreased expression of CTLA-4 by Treg 
cells promotes anti-tumor immunity [89, 90].   
 
Programmed Cell Death 1 (PD-1) 
 Programmed Cell Death 1 (PD-1) is an inhibitory receptor, whose ligands PD-L1 (B7-
H1) and PD-L2 (B7-DC) share sequence homology with co-stimulation receptors CD80 (B7-1) 
and CD86 (B7-2) [91-94].  PD-1 is constitutively expressed on Treg cells and its expression is 
induced on activated effector T cells, with ligand binding producing differential effects based on 
regulatory or effector subset [94, 95].  PD-L1 is constitutively expressed on lymphocytes and 
APCs, is induced in many cell types by type I and type II interferons (IFN), and can be expressed 
by many tumor cell types and tumor stroma [94, 96].  PD-L2 is more restricted to inducible 
expression on APCs following IFN-γ, IL-4, and GM-CSF-mediated activation [94, 95].   
 In effector T cells, ligand binding of PD-1 results in phosphorylation of PD-1 
intracellular inhibitory domains, and leads to dephosphorylation of, and decreased signaling by, 
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the TCR complex [92, 94, 95].  In addition, PD-1 ligation inhibits phosphatidyl inositol 3 kinase 
(PI3K) activation and subsequent Akt activation.  This effect not only limits T cell:APC duration 
times needed for T cell activation, but T cell:target cell duration times needed for effective 
killing.  As with CTLA-4, PD-1 ligation by naïve CD4+ T cells can drive differentiation into iTreg 
cells [82].  In Treg cells, high levels of PD-1 expression drive Treg proliferation [97].   
 
1.6 Methods of Immunotherapy 
 There are three broad classes of anti-tumor immunotherapy currently in use.  These 
methods range from the non-specific, to the patient-specific, to the antigen-specific.  Each class 
possesses its own promises and drawbacks. 
 
Non-Specific Immunotherapy 
 Coley’s toxin is one example of non-specific immunotherapy, using immune agonists or 
cytokines to broadly activate the immune system.  However, other examples are being studied or 
are already in practice.  For instance, high dose IL-2 was the first treatment to affect outcome of 
metastatic melanoma [98, 99].  A small minority of patients (4-6%) treated with high dose IL-2 
experience long-term disease-free survival, with 15-20% of patients experiencing an objective 
response [100].  The use of anti-CTLA-4 antibody (ipilimumab) was shown to be effective in 
phase III trials of metastatic melanoma, increasing overall survival in treated patients [101, 102].  
Two anti-PD-1 antibodies, nivolumab and lambrolizumab, are currently being tested in phase III 
trials of metastatic melanoma [103, 104].  Phase II data with these antibodies looks promising, 
with objective response rates of 31% and 38%, respectively [105].  In a phase I study, 
combination therapy with ipilimumab and nivolumab had higher anti-tumor activity than either 
 19 
agent alone, with an objective response rate of 40% and stable disease or better outcome 
experienced by 65% of patients [105, 106]. 
 The use of non-specific immunotherapy has its drawbacks, unfortunately.  As expected 
by its lack of antigen specificity, systemic activation of the immune system leads to many 
immune-related side-effects, including rash, pruritis, hepatitis, and renal toxicity.  Non-specific 
immunotherapies also produce better outcomes for cancers that are already highly immunogenic.  
In these cases, non-specific immunotherapy can accentuate an endogenous immune response, but 
are lacking in their ability to initiate one.  Some treatments may even have tumor-promoting 
effects.  In patients with melanoma, IL-2 therapy was shown to increase peripheral Treg cell 
number, as well as promote their migration to the tumor site [107, 108].  Although these findings 
are not surprising given constitutive IL-2R (CD25) expression by Treg cells, their induction may 
have deleterious effects on patient outcome that have not been considered or evaluated.  Even 
given these concerns, non-specific immunotherapy holds the greatest promise for the tumors in 
which an antigen is not known, precluding the use of the two methods described below. 
 
Adoptive Cell Therapy 
 A second type of immunotherapy utilizes the adoptive transfer of autologous tumor-
reactive lymphocytes.  In this method, fragments of resected tumor are digested in order to 
isolate tumor-antigen-specific lymphocytes [109].  These cells are activated and expanded in 
vitro and then returned to the patient.  This ex vivo culture allows the cells to be expanded 
without the immunosuppressive mediators present in the tumor microenvironment.  Before the 
autologous transfer, patients are conditioned with lymphodepleting chemotherapy or total body 
irradiation to deplete Treg cells present in the tumor, activate APCs following radiation-induced 
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gastrointestinal damage, and create space for the homeostatic proliferation of adoptively 
transferred lymphocytes [109].  In trials of metastatic melanoma, objective response rates as high 
as 72% have been achieved [110]. 
 Although this method has proven effective, its clinical utilization has been slow.  The 
patient-specific nature of this treatment precludes the possibility of large-scale production 
necessary for commercialization.  This method is also highly labor intensive, requiring vast 
amounts of laboratory expertise in the culture and differentiation of effector T cells.  As such, 
few studies have attempted to use this method in large-scale clinical trials.  Finally, as with non-
specific immunotherapies, this treatment works best for immunogenic tumors.  Therefore, 
adoptive cell transfer may not be useful in cancers that do not recruit high numbers of tumor-
specific lymphocytes or for tumors using immunosuppressive mechanisms that cannot be 
overcome with lymphodepleting conditioning. 
 A recent method of adoptive cell transfer uses chimeric antigen receptor (CAR) 
technology.  This technology enables the genetic engineering of T cells to express the 
extracellular domain of immunoglobulin ligated to the intracellular domain of the TCR [111].  
These new T cells can then specifically bind antigen that is not presented in the context of MHC, 
allowing direct recognition of target cells.  The intracellular domain of the CAR can also be 
engineered to contain co-stimulatory domains, abrogating the need for APC co-stimulation.  
Following CAR binding, the natural perforin and granzyme pathways inherent to T cells permit 
direct target cell killing.  For cancers in which an antigen is known and relatively tumor-specific, 
such as CD19+ B cell chronic lymphocytic leukemia, CAR therapy can result in complete and 
sustained remission [112, 113].  Not without its own side effects, CAR therapy can result in 
tumor lysis syndrome from the extremely effective treatment.  In addition, targeted killing of 
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CD19+ cells results in the depletion of all normal CD19+ B cells, leading to a marked reduction 
in the ability to generate plasma cells [112-114].  Even with these side-effects, CAR technology 
remains a promising therapy for patients. 
 
Therapeutic Vaccines 
 The third method of immunotherapy, therapeutic vaccines, attempts to overcome the 
shortcomings of non-specific immunotherapy and adoptive cell therapy by generating a tumor-
specific immune response in vivo.  Two examples of therapeutic vaccines that have been studied 
are dendritic cell vaccines and Venezuelan Equine Encephalitis viral replicon particles. 
 Dendritic cells are one of the few professional APCs that can stimulate both B and T 
cells, and are critical for naïve T cell stimulation and activation [1, 115].  As with adoptive T cell 
transfer, DCs can be generated, primed, and activated ex vivo, without being exposed to the 
immunosuppressive tumor environment.  DCs are primed by loading a known TAA or by 
incubating with tumor cell lysates, allowing for processing and presentation of numerous 
unknown tumor antigens [116].  DCs can then be matured with strong activating agonists, such 
as TNF or LPS to increase antigen presentation and co-stimulation.  Once returned to the patient, 
these DCs should be able to promote anti-tumor responses, dependent on the antigen presented.  
Unfortunately, these activated, tumor-specific DCs rarely result in an anti-tumor response, due to 
local immunosuppressive mediators induced in the tumor microenvironment [15, 116-118]. 
 Viral vector vaccines aim to take advantage of the natural PAMPs and DAMPs 
associated with an active viral infection.  These vectors transduce expression of TAAs in the 
context of a viral infection, allowing for efficient tumor antigen presentation on both class I and 
class II MHC [119].  These vaccines also possess the ability to activate B cells and promote 
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antibody production.  One viral vector, derived from the Venezuelan Equine Encephalitis (VEE) 
virus, exhibits a natural tropism for dendritic cells and B cells.  This tropism effectively results in 
the generation of therapeutic DC vaccines in vivo, without the need for ex vivo DC culture.   
 In order to circumvent the limitations of other viral vector systems, viral replicon 
particles (VRP) have been generated from the VEE virus [120-122].  These VRP contain the 
gene for the TAA of interest without the structural genes necessary viral assembly.  In this way, 
VRP infection results in target cell translation, processing, and presentation of the tumor antigen, 
but not the generation of new viral particles.  Multiple doses of VRP can then be given over time 
to continually promote an anti-tumor response, without the need for retroviral gene insertion.  
However, completed phase I and phase II trials have reported disappointing clinical efficacy 
[123, 124]. 
 
Unbalancing Both Sides of the Scale 
 As we discussed, the key to any effective immune response is maintaining the correct 
balance of activating and suppressing signals to promote the appropriate response.  In the case of 
cancer immunotherapy, this necessitates not only increased T cell activation against the tumor, 
but decreased immunosuppression by the tumor.  The three immunotherapy methods described 
above have a variable effect on the ability to promote an anti-tumor response.  However, these 
methods do not attenuate the immunosuppressive tumor microenvironment.  In the solid tumor 
setting, such profound local immunosuppression often overpowers the treatment, and the scale 
remains tipped towards tumor progression.  In order to generate an effective treatment, multi-
modality therapy that can unbalance both sides of the scale will be necessary to provide 
effective, durable results. 
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1.7 Intrinsic Breast Cancer Subtypes  
 Over 200 thousand women are diagnosed with breast cancer in the United States every 
year, and 20% of these women will eventually succumb to their disease [125].  These numbers 
make breast cancer the leading cancer diagnosis and the second-leading cause of cancer death in 
women.  Early diagnosis and targeted therapy, both hormonal and immunologic, are critical for 
the effective treatment of this disease.  However, the survival benefit from recent therapeutic 
advances has been disproportionately distributed across the breast cancer subtypes [126].   
 Triple negative breast cancers, lacking expression of Estrogen Receptor (ER), 
Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2), continue 
to carry the worst prognosis, due to higher grade at diagnosis, lack of targeted therapy, and an 
increased propensity for relapse and early metastasis [126].  Using gene expression array 
analyses of tumor cells, the Perou laboratory at UNC-Chapel Hill has distinguished 6 intrinsic 
subtypes of breast cancer: Luminal A, Luminal B, Normal-like, HER2, Basal-like, and Claudin-
low [127].  Basal-like and claudin-low tumors, which make up the majority of triple negative 
breast cancers, are separated from the other intrinsic subtypes by increased expression of 
proliferation markers and immune genes [128, 129].  Claudin-low tumors are further separated 
from basal-like tumors by their decreased expression of cell-cell adhesion markers, increased 
epidermal-to-mesenchymal transition markers, and stem cell-like characteristics [130, 131]. 
 The intrinsic subtypes of breast cancer exhibit differential immune infiltration based upon 
their classification [132-134].  Luminal A and luminal B subtypes have no appreciable immune 
infiltrate, but account for approximately 60% of newly diagnosed breast cancers [135, 136].  
Conversely, basal-like and claudin-low subtypes account for 20-30% of newly diagnosed 
cancers, and their increased immune infiltrate correlates with decreased survival compared to 
 24 
Luminal A and Luminal B tumors [127, 136].  The inclusion of the Luminal subtypes in trials 
testing the efficacy of immunotherapies for breast cancer biases towards a null result.  Therefore, 
it is important to study the pathophysiology of these cancers in a subtype specific manner.  
Mouse models of the intrinsic breast cancer subtypes afford us this opportunity. 
 
1.8 Genetically Engineered Mouse Models 
 Previous mouse models of breast cancer relied on xenograft transplant of human samples 
into immunocompromised mice.  While this allowed researchers to study tumor cell intrinsic 
physiology, it failed to take into account the effect of tumor extrinsic factors on tumor growth, 
such as alterations in the tumor stroma and characteristics of the immune cells found at the site 
of tumor growth.  However, the differential immune infiltrate exhibited by human samples 
shows that a competent immune system may have a profound effect on tumor growth and 
pathophysiology.  Genetically engineered mouse models (GEMMs) provide us with the 
opportunity to study breast cancer, in a subtype specific approach, in a natural and 
immunocompetent host. 
 The oldest of these models used insertion of rat-Neu, the rat homolog of human HER2, 
into an FVB/N mouse.  This gene, under the control of the mouse mammary tumor virus 
(MMTV) promoter, results in overexpression of Neu in that mammary tissue and spontaneous 
development of Neu-driven tumors [137-139].  Further, thymic expression of Neu leads to 
central deletion of Neu-reactive T cells, mimicking the immune tolerance to HER2 seen in 
human patients.  Injection of the cell line generated from one such spontaneous tumor, NT2, 
allows evaluation of tumor growth and immune infiltrate in a standardized fashion [138, 139]. 
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 Three genetically engineered mouse models of the other intrinsic breast cancer subtypes 
were generated on a p53-/- BALB/c mouse background.  These mice generate spontaneous 
tumors that, depending on their cell of origin and subsequent mutations, can be gene arrayed and 
classified by intrinsic subtype.  This background has provided models of the Luminal A, Basal-
like, and Claudin-low subtypes, termed 2250, 2225, and T11, respectively [130].  These models 
are propagated in vivo and display stable and predictable gene profiles.  These p53-/- models, as 
well as the Neu-N model, recapitulate the diversity of the intrinsic subtypes at the genetic level 
and allow us to study how the immune system affects tumor growth and pathogenesis in a 
subtype specific manner. 
 
1.9 Dissertation Aims 
 The key to successful immunotherapy of any disease is achieving the appropriate balance 
between activation and suppression of the immune system.  The important of this balance can be 
demonstrated using two disease models, in which opposite effects are desired.  In graft-versus-
host disease, we must increase immunosuppression enough to prevent GvHD, without sacrificing 
the GvL effect.  In cancer treatment, we must increase immunoactivation while simultaneously 
decreasing tumor-mediated immunosuppression.  In both diseases, this can be achieved by 
altering cell migration, but the target of the alteration is cell-specific and dichotomous.  In order 
to study these differences, we evaluated three projects related to effective immunotherapy.  In the 
first, we evaluated the kinetics of effector T cell and Treg cell activation in secondary lymphoid  
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tissue following allogeneic HSCT.  In the second, we attempted to decrease effector cell 
migration from secondary lymphoid tissue to target organs following HSCT by targeting the 
actin cytoskeleton machinery.  In the third, we attempted to decrease migration to and activity of 
Treg cells in the tumor site in order to promote anti-tumor immunity.  
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CHAPTER TWO 
INTRAVITAL IMAGING OF DONOR ALLOGENEIC EFFECTOR AND 
REGULATORY T CELLS WITH HOST DENDRITIC CELLS DURING GVHD1 
2. 
2.1 Introduction  
 Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred treatment for 
patients with high risk acute leukemia, relapsed leukemia, and congenital or acquired bone 
marrow failure syndromes, and it has been used increasingly for the treatment of individuals with 
low grade lymphoid malignancies [1].  More widespread use of allogeneic HSCT is limited by 
the occurrence of acute and chronic graft-versus-host disease (GvHD).  GvHD is mediated by 
donor T lymphocytes recognizing disparate minor or major histocompatibility complex (MHC) 
antigens in the host.  Donor T cells are activated in secondary lymphoid organs and migrate to 
GvHD target organs.  These cells mediate a pro-inflammatory process that recruits other immune 
cells to target organs, leading to GvHD [2].  However, the kinetics of activation of donor Tcons 
and their interaction with host DCs have not been studied at a cellular level.  
 The interaction of T cells with antigen presenting cells (APCs) has been evaluated in vivo 
using multiphoton laser scanning microscopy (MPLSM).  Early studies demonstrated that 
                                                
1 This research was originally published in Blood.  Lin KL, Fulton LM, Berginski M, West ML, 
Taylor NA, Moran TP, Coghill JM, Blazar BR, Bear JE, Serody JS. Intravital Imaging of donor 
allogeneic effector and regulatory T cells with host dendritic cells during GVHD. Blood. 
2014;123:1604-1614. © The American Society of Hematology. 
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pathogen-specific transgenic T cells in the lymph node (LN) had a tri-phasic mode of movement 
and activation [3-5].  After the entry of T cells into the lymph node, T cells formed brief contacts 
with DCs in a screening phase that lasted for approximately 4-8 hours.  Following screening, 
pathogen-specific T cells established long-lasting arrest on DCs for more than an hour, and this 
phase lasted 8-12 hours.  After the phase of long-lasting interactions with DCs, T cells 
proliferated, expanded, and differentiated.  During activation, the interaction of T cells with DCs 
was again characterized by very brief interactions.  Later, several studies found that relatively 
high concentration of antigen can induce rapid or immediate arrest of transgenic T cells on DCs, 
without an initial phase of T cell screening [6-8].  These data would suggest that T cell screening 
of DCs is not obligatory when antigen is abundant [9].  However, the relevance of these findings 
to immunity with diverse T cell repertoires is not clear.  All of the studies on T-DC interaction 
using MPLSM have utilized transgenic T cells.  Further, some of these studies used 
concentrations of antigen that were not in the physiologic range, with only a small population of 
APCs capable of presenting antigen.  The behavior of naïve T cells with a broad repertoire has 
not been well characterized by MPLSM.  In addition, there are no studies that have used 
MPLSM to evaluate a systemic inflammatory process like acute GvHD.  
 Over the past 15 years, a new subset of CD4+ T cells that express the transcription factor 
FoxP3 and suppress the activation and proliferation of other T cells has been characterized [10-
12].  Work from our group and others has shown that these regulatory T cells (Tregs), if given in 
sufficient numbers, can prevent the onset of acute GvHD [13-17].  These findings have led to 
several early phase clinical trials in which regulatory T cells were given to recipients to prevent 
GvHD [18-20].  While a limited number of patients were treated in these trials, the initial data 
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suggested that Tregs diminish GvHD without increasing the risk of disease recurrence or 
infection.   
 Interestingly, despite their clinical use, it is still unclear how Tregs function to prevent 
GvHD.  Our group showed that Tregs with high levels of expression of L-selectin, a protein 
critical for the migration of lymphocytes into secondary lymphoid tissue (SLT), were much more 
potent at preventing GvHD than those with a lower level of L-selectin expression [17].  This 
suggested that Tregs needed to migrate to SLT for their activity, although the mechanisms by 
which they interfere with Tcon activation in SLT are unknown.  Furthermore, the use of Tregs has 
been hampered by their low numbers in vivo and the difficulty of expanding these cells ex vivo.  
CD4+ T cells in the presence of transforming growth factor (TGF)-β1 and interleukin 2 (IL-2) 
can be polarized to become FoxP3-expressing inducible Tregs (iTregs) and were shown to inhibit 
GvHD in a xenogeneic transplant model [21].  These cells, which are more easily generated and 
expanded ex vivo, have attracted interest as a potential therapy for the prevention of GvHD.  
However, pre-clinical studies using these cells were not successful in preventing GvHD, due in 
part to the ability of these cells to revert to effector T cells post-transplantation [22].  At this 
time, it is not clear if the function of iTregs is intrinsically different in their ability to suppress 
GvHD, or if their lack of function is mediated by FoxP3 instability or some other mechanism.   
 This study sought to determine the processes by which alloreactive T cells are activated 
by DCs in SLT.  Additionally, we examined how Tregs mitigate this activation and whether 
endogenous Tregs or in vitro-induced Tregs use the same mechanisms to suppress donor T cell 
activation.  
 
 40 
2.2 Methods 
Mice 
 C57BL/6J (B6), BALB/cJ, IL-10-/-, CD11c-DTR-EGFP, and CD11c-YFP mice were 
purchased from The Jackson Laboratory.  FoxP3-mRFP (FIR) mice were kindly provided by Dr. 
Yisong Wan.  
 
Transplantation systems 
 Donor T cells and T cell-depleted (TCD) bone marrow (BM) cells were prepared as 
previously described [23].  Recipient mice were irradiated at 800 cGy (BALB/c background) or 
950 cGy (B6 background) one day prior to transplantation with 3-5 million donor T cells (or 3 
million total T cells, with 2 million Tregs) and 4-5 million TCD BM cells.  Donor wild-type (WT) 
or IL-10 -/- Treg cells were prepared as previously described [17].  Because Tregs in 8 week old 
mice are composed of predominantly natural Tregs and a much smaller population of inducible 
Tregs, we have termed these cells endogenous Tregs (eTregs).   
 
Generation of inducible Tregs 
 CD4+ T cells were purified from lymph nodes and spleens using negative selection by 
MACS.  CD25-CD4+ T cells were then cultured for 4 days in a 24-well plate in complete 
DMEM, containing 10% FBS, 100 U/ml of IL-2, and 10 ng/ml of TGF-β.  
 
Intravital imaging 
 CD11c-DTR-EGFP mice (BALB/c background) or CD11c –YFP mice (B6 background) 
were lethally irradiated (800 or 950 cGy, respectively).  The next day, mice were transplanted 
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with TCD BM cells, CMTPX (Invitrogen)-labeled naïve T cells and unlabeled naïve T cells from 
B6 mice.  In different experiment settings, mice were transplanted with different combination of 
labeled T cells, labeled Tregs, or labeled iTregs, with different unlabeled control cells.  At 2-8 and 
18-24 hours after transplantation, recipient mice were anesthetized and the popliteal LN imaged 
using the FV1000MPE microscope (Olympus).  Body temperature was maintained at 37 °C by 
an electric warming plate.  A plaster cast was put on the hind leg to minimize the respiratory 
movements and microscopic surgery was done to expose the LN [24].  Five z-planes separated 
by 3-5 µm were collected at 60 time points, making each movie approximately 30-35 minutes.  
Images were analyzed using Imaris and Matlab software.  
 
More experimental details can be found in the supplementary methods.  
 
2.3 Results 
Allogeneic donor T cells do not screen for host DCs in GvHD.   
 Our group has shown previously that the infusion of 5 x 105 B6 T cells mediated lethal 
GvHD in irradiated BALB/c recipients, with all animals euthanized by day 25 post-bone marrow 
transplant (BMT) [25].  To observe the interactions between donor Tcons and host DCs during the 
initial phase of GvHD in this model, we used intravital imaging of popliteal LNs of recipient 
mice.  CD11c-DTR-GFP mice (BALB/c background) were irradiated and given labeled B6 
donor T cells with T cell-depleted (TCD) bone marrow (BM) cells one day after irradiation.  
After transplant, the recipient mouse was anesthetized and the popliteal LN surgically exposed 
and observed using the Olympus FV1000 (Fig. 2.1a and Suppl. Fig. 2.S1a).  We found that the 
instantaneous and mean velocity of donor allogeneic T cells was diminished at 2-3 hours after 
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transplantation, comparable to that found at 8-9 hours post-transplant (Fig. 2.1b and 2.1c).  The 
median displacement ratio was low from 2-3 to 8-9 hours post transplant (Fig. 2.1d).  Combined 
with similar contact time between donor T cells and host DCs throughout the first 8 hours (Fig. 
2.1e and Suppl. Movie 1), these data suggest that allogeneic donor T cells require very little time 
screening DCs before forming long-term interactions after allogeneic BMT.  However, the 
percentage of T-DC conjugates that lasted more than 30 minutes was modestly lower at 2 hours 
compared with the later time points (Suppl. Fig. 2.S1b), suggesting a small percentage of T cells 
did require screening of DCs presenting cognate alloantigens.  Late, a subset of donor T cells 
began to increase velocity and displacement 20-24 hours post-transplant (Suppl. Movie 2).  By 
24 hours after transplantation, the majority of T cells were moving rapidly (Fig. 2.1c).  These 
results indicated that the kinetics of allogeneic Tcon-DC interaction do not require a prolonged 
phase of short encounters to screen for antigen-expressing DCs, supporting the studies using 
transgenic TCR T cells with abundant antigen [6].  The stable contact phase between T cells and 
DCs ends at approximately 24 hours post-transfer [3, 5].  
 Syngeneic T cells had a higher instantaneous velocity and displacement ratio than 
allogeneic T cells (Fig. 2.1b and 2.1d), indicating that differences in velocity and displacement 
ratio were not due to conditioning therapy alone.  However, there was an effect of conditioning 
therapy, as syngeneic T cells had diminished velocity in irradiated recipients compared with 
syngeneic T cells given to non-conditioned recipients (Fig 2.1b).  To examine the effect of a 
different type of conditioning, we repeated imaging using recipient mice conditioned with 
chemotherapy.  CD11c-DTR-GFP mice were given i.p. cyclophosphamide before transplant and 
imaging.  We found comparable results between donor T cell and host DC interactions in mice 
conditioned with chemotherapy or radiation.  The donor T cells had diminished velocity as early 
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as 2 hours post-transplant and contact time between T cells and DCs was not significantly 
different up to 8 hours post-transplant (Fig. 2.2a – 2.2c).  The percentage of T-DC conjugates 
that lasted more than 30 minutes at 2 hours was also slightly lower than at other time points 
(Suppl. Fig. 2.S1c), consistent with the data after irradiation.  These data indicate that allogeneic 
donor T cells follow very similar kinetics in host LNs after transplant, which is independent of 
the process used for conditioning.   
 To confirm that these findings were not model dependent, we evaluated the velocity of 
BALB/c T cells and their contact time with DCs after transplantation into CD11c-YFP B6 
recipient mice.  As shown (Fig 2.2d – 2.2f), BALB/c Tcons have analogously low instantaneous 
velocity, decreased mean velocity, and similar contact time with DCs from 2 to 8 hours post-
transplant.  The percentage of T cell-DC interactions lasting more than 30 minutes is lower at 2-3 
hours compared to 5-8 hours, but this difference was not significant (Suppl. Fig. 2.1d).  Thus, 
these data indicate that when antigen is not limiting, T cells need a very short time screening 
DCs before they form stable interactions.  Further, this finding was not model dependent.  
 
Co-transplant of Tregs disrupts Tcon-DC interactions.  
 Several human clinical trials using eTregs with HSCT have shown that Treg therapy given 
prior to, or at the time of HSCT, was associated with a reduced risk of acute GvHD [18-20].  Co-
transfer of Tregs at the same time as transplantation of donor Tcons and TCD BM reduced GvHD 
in murine models [13, 17].  Therefore, we investigated how eTregs impede donor T cell activation 
in real time in vivo.  Over 85% of our purified eTregs expressed FoxP3 and they suppressed Tcon 
proliferation in vitro (Suppl. Fig. 2.2a and 2.2b), which is analogous to the purity typically found 
following column-based purification clinically.  We administered labeled Tcons with unlabeled 
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eTregs (Tcons:Treg ratio of 3:2) to irradiated CD11c-DTR-GFP mice.  We found that Tcons 
transferred with eTregs have a significantly increased velocity by 6-7 hours post-transplant, 
compared with Tcons transferred alone (Fig. 2.3a and Suppl. Movie 3).  Additionally, the 
movement of Tcons transferred with eTregs is less confined (Fig. 2.3b).  The interactions between 
DCs and Tcons were substantially altered, with reduced median DC contact time when given with 
eTregs (Fig 2.3c).  Furthermore, when infused with eTregs, less than 20% of Tcons are in contact 
with DCs for more than 30 minutes.  By comparison, 30% or more Tcons interact with DCs for 30 
minutes or longer when transferred without concomitant eTregs (Suppl. Fig 2.S3a).   
 Next, we evaluated the interaction of donor eTregs with host DCs (Fig. 2.3d – 2.3g).  The 
mean velocity of eTregs in the LN was similar to that of Tcons from 3-24 hours post-transplant 
(Fig. 2.3e).  Eight hours after transfer, approximately 30% of eTregs were in contact with host 
DCs for at least 30 minutes; approximately 21 hours after transplant, 15% of the eTregs were still 
in contact with DCs for at least 30 minutes.  These findings are comparable to the percentage of 
lasting T-DC interactions found with transfer of Tcons alone (Suppl. Fig. 2.S3b and Suppl. Movie 
4).  However, eTregs displayed much lower velocity than Tcons when they were examined together 
(Fig. 2.3g).  Combined with the data showing that contact duration between Tcons and DCs is 
reduced by eTreg transfer, we conclude that one method by which eTregs function is to diminish 
the early interaction (4-8 hours post-transplant) of Tcons with host DCs.   
 To determine if the contaminating 15% of the cells given with our eTreg infusions 
affected these results, we sort purified Tregs from FIR mice using the expression of mRFP to 
greater than 95% purity (Suppl. Fig. 2.S2c).  No differences were found between the mean 
velocity, contact time, or displacement ratio following the use of highly purified Tregs or less 
purified, more clinically relevant Treg preparations (data not shown).   
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Inducible Tregs also reduce Tcon-DC interactions.  
 Murine Tregs can be induced in vitro by stimulating CD4+CD25− T cells in the presence of 
TGF-β1 and IL-2.  Transfer of these iTregs suppresses allergic pathogenesis [26, 27].  However, 
several groups have shown that infusion of iTregs did not prevent acute GvHD in animal models, 
hypothesized to be due to instability of the iTreg phenotype [22].  Whether iTregs intrinsically 
function differently than eTregs is not clear.  Thus, we examined the effect of iTreg transfer on the 
movement of donor T cells and their interaction with host DCs.  The percentage of iTregs 
generated ex vivo and their function in suppressing proliferation was similar to eTregs (Suppl. Fig. 
2.S2d and 2.S2e).  Interestingly, the velocity of Tcons in the presence of iTregs was statistically 
greater in the first 4-5 hours post-transplant, compared with the velocity of Tcons in the presence 
of eTregs.  This correlated with a statistically significant difference in the displacement ratio of 
Tcons in the presence of iTregs, compared with eTregs (Fig. 2.4a and 2.4b).  As shown in Figure 2.4c 
and Supplementary Figure 2.S3c, iTregs reduced the interactions between Tcons and DCs 
comparable to that found using eTregs at 8 hours after transplant (Suppl. Movie 5).   
 We also examined the kinetics of iTregs in LNs post-transplant (Fig. 2.4d).  The mean 
velocity of iTregs late post-transplant differed from eTreg after transplant, as iTreg velocity 
remained diminished even 21 hours after transplant (Fig. 2.4e).  However, the longitudinal 
interaction with DCs was equal between eTregs and iTregs from 8-24 hours post transplant (Fig 
2.4f, Suppl. Fig. 2.S3d, and Suppl. Movie 6).  These data suggest that iTregs function similar to 
eTregs early post-transplantation.   
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IL-10 is required for the disruption of T-DC interaction by eTregs.  
 IL-10 is one of the humoral factors that Tregs use to suppress immunity in vivo [28].  IL-
10-deficient Tregs have been found to be less effective in preventing acute GvHD in animal 
models [29].  In addition, IL-10 has been shown to directly suppress the maturation and 
stimulatory functions of DCs [30-32].  Therefore, we sought to examine whether IL-10-/- eTregs 
had decreased ability to block T-DC interaction in our intravital experiments.  We found that the 
co-transplant of IL-10-/- eTregs with Tcons failed to increase the velocity and displacement ratio of 
Tcons (Fig. 2.5a and 2.5b).  IL-10-/- eTreg also failed to decrease the contact time and the 
percentage of T-DC conjugates between Tcons and DCs (Fig. 2.5c and Suppl. Fig. 2.S3e).  Our 
data indicate that eTreg production of IL-10 was critical for the effects of donor Tregs on the 
interaction between donor Tcons and host DCs.  
 
Both eTreg and iTreg decrease CD86 and CD54 on host DCs and diminish host DC number.  
 One potential mechanism for the function of Tregs in vivo is to directly interact with Tcons 
to inhibit T cell activation.  To determine whether this is found in the allogeneic setting, we 
evaluated the interaction between Tcons and Tregs in the first 24 hours post-transplant.  During this 
time frame, we were unable to find a significant interaction between these cells (Suppl. Movie 
7), which is consistent with previous studies [33-35].  Since we observed that Tregs interact with 
DCs in vivo, we investigated the expression of co-stimulatory molecules and molecules involved 
in synapse formation by host DCs after BMT.  The molecules examined included CD80, CD86, 
CD40, CD54, CD70, B7-H3, and B7-H4.  On day 1 after transplant, there was no difference in 
the expression of co-stimulatory molecules from DCs isolated from the spleen of mice 
transferred with Tcons or eTregs (data not shown).  However, a modest statistically significant 
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decrease was found in the expression of CD69 by both activated donor CD4+ and CD8+ Tcons in 
the presence of eTregs (data not shown).  No difference on day 1 was found in the expression of 
CD25 or CD44 by donor T cells (data not shown).  In contrast, on day 2 post-transplant, we 
found that DCs from recipient mice receiving eTregs had down-regulated CD86 and CD54 on host 
splenic DCs (Fig. 2.6a and 2.6b).  The transplantation of iTregs also reduced the expression of 
CD86 and CD54 on host DCs isolated from skin draining LNs (Fig. 2.6c and 2.6d).  No 
differences were found in the other proteins evaluated.  Evaluations past day 2 post-transplant 
could not be performed due to the paucity of host DCs present.   
 Interestingly, and somewhat unexpected, while evaluating the effect of Tregs on the 
expression of co-stimulatory molecules, we found that infusion of Tregs led to a decrease in the 
number of host DCs, compared with the infusion of Tcons.  The average decrease in host DCs was 
50% on day 2 after the infusion of eTregs or iTregs, compared to Tcons (Fig 2.7a and 2.7b).  We then 
examined the death rate of DCs and found that the infusion of eTregs and iTregs induced a 
statistically significant increase in DCs expressing 7AAD (Fig. 2.7c – 2.7e).  eTregs in the 
recipient spleen expressed FasL and perforin (Fig. 2.7f and 2.7g) while iTregs generated in vitro 
only expressed FasL (Suppl. Fig. 2.S4).  This suggests that one process by which host DCs were 
eliminated post-transplant was through Treg-mediated killing potentially via either FAS ligand or 
perforin [36]. 
 
2.4 Discussion 
 Allogeneic HSCT is the most effective cellular therapy for the treatment of specific 
malignant diseases.  One of the significant complications that occur after allogeneic HSCT is the 
occurrence of acute GvHD [2, 37].  Multiple groups have shown that the interaction of donor T 
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cells with host APCs is critical for the induction of acute GvHD [38-40].  Here, we have 
evaluated this interaction in vivo using MPSLM.  We found that donor allogeneic Tcons do not 
require a prolonged screening phase prior to specific stable interactions with host DCs.  Tcons 
establish long contacts with DCs two hours after arrival in the LN.  The time for stable contact 
duration between Tcons and DCs in this systemic model is about 20-24 hours.  The frequency of 
long-term T cell-DC interactions is much lower at 24 hours after transplant while alloantigens 
are still abundant, indicating that alloreactive T cells become refractory to further TCR 
stimulation after initial activation.  We also found that eTregs and iTregs can significantly interrupt 
the interactions between Tcons and DCs, which has been observed for eTregs in organ-specific 
autoimmunity.  When used as the sole population of T cells after HSCT, eTregs, iTregs and Tcons 
have comparable interactions with host DCs.  However, at later time points (greater than 20 
hours post-transplant), iTregs have lower velocity than the other two cell types, which is most 
likely due to their previous activation ex vivo.  Finally, we have found that eTregs and iTregs down-
regulate the expression of critical co-stimulatory and adhesion molecules by host DCs and 
induce host DC death.  
 A number of different groups have performed elegant experiments in pathogen-specific 
transgenic systems that defined the three phases of T cell activation [3-5].  The interpretation for 
the initial phase of short interaction between T cell and DCs was that this was needed for 
pathogen-specific T cells to sample APCs presenting the correct peptide:MHC complex for T 
cell activation.  Thus, 8-12 hours after this initial phase, pathogen-specific T cells have identified 
APCs presenting the correct peptide:MHC complex and engage in a prolonged period of contact 
necessary for T cell activation.  However, subsequent studies using high concentrations of 
antigen failed to detect an initial phase of transient interactions and instead visualized the 
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formation of long-lived T cell–DC contacts very early in the response [6, 7].  Our study found 
that the majority of T cells were still in the lumen of the high endothelial venule of the lymph 
node 1-2 hours after transplant (data not shown).  Therefore, we started our analysis 2 hours after 
transplant.  A subset of T cells, approximately 20-25% of the T cells imaged, maintained 
prolonged interactions with host APCs for more than 30 minutes starting 2 hours post transplant 
(Suppl. Fig 2.S1b).  Although the percentage of these long-interacting T cells increased to 25-
30% from 2 hours to 3 hours, it indicated that the majority of alloreactive T cells had already 
established stable contact with DCs 2 hours after transplant.  Thus, we were not able to 
demonstrate a distinct screening phase of transient interactions in the allogeneic setting.  We 
believe that the absence of this screening phase is because alloreactive T cells can be activated 
by any APC.  Our data support a paradigm for T cell activation in the presence of antigen 
abundance, in which the scanning of APCs is not necessary [9].  This finding would also explain 
why prophylactic drugs need to be present for a significant amount of time prior to the infusion 
of donor T cells, as the expansion of donor T cells occurs almost immediately after their 
infusion.  
 The infusion of Tregs has very quickly moved into the clinic, with multiple groups in the 
United States and abroad using this approach to prevent acute GvHD [18-20].  Interestingly, this 
is being performed despite a limited understanding regarding how these cells function in vivo.  
Our work suggests that Tregs use multiple mechanisms to prevent Tcons activation in vivo, centered 
on disruption of Tcon-DC interactions.  DCs are potent APCs due to multiple factors, including 
the ability to take up antigen, the expression of co-stimulatory molecules critical for T cell 
activation, and the generation of cytokines critical to polarizing a T cell response [41].  Our data 
indicate that the prolonged interaction of donor Tcons with host DCs is markedly diminished in 
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the presence of donor eTregs or iTregs.  We believe that this is one critical mechanism by which 
Tregs function in secondary lymphoid tissue to prevent acute GvHD.  Interestingly, iTregs 
functioned initially better than eTregs, probably due to their prior activation ex vivo.   
 We found additionally that donor Tregs can reduce the expression of critical co-
stimulatory and adhesion molecules, such as CD86 and CD54.  It is interesting that previous 
investigations have identified CD28:CD80/CD86 and LFA-1:CD54 interactions as important for 
the generation of the immunological synapse (IS) [42].  Therefore, one method by which Tregs 
could block Tcon activation is by altering proteins present in the IS and increasing the signaling 
threshold needed to activate Tcons.  Our group is currently evaluating this hypothesis.  
 Another method we found that may be responsible for the function of Tregs is the 
induction of death of host DCs.  Previously, Boissonnas, et al., evaluated the effect of Tregs on the 
viability of DCs from tumor-draining lymph nodes [36].  They found that reducing Treg numbers 
using anti-CD25 antibody or the administration of diphtheria toxin to FoxP3-DTR mice led to an 
increase in DCs.  Death of DCs in this model was dependent on perforin expression by Tregs.  Our 
data suggest that the administration of Tregs may lead to an early increase in the death of host 
DCs, consistent with Boissonnas’ previous finding.  Our ex vivo studies indicate that iTregs and 
eTregs have significant expression of FAS ligand and more modestly, perforin, which may 
mediate the death of host DCs found in this study.   
 The fact that iTregs can interrupt Tcon-DC interaction better than eTregs early post-
transplant demonstrates that they are intrinsically functional in vivo.  It is advantageous to use 
these iTregs in human cellular therapy because they can be generated more easily and in larger 
numbers than eTregs.  However, the inflammatory nature of GvHD may create an environment 
that is not conducive to maintaining the expression of FoxP3 by iTregs or support their survival 
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over time.  This would suggest that separating iTreg infusions from conditioning therapy may 
improve their function.   
 Finally, we showed that IL-10 is required for Treg-mediated disruption of Tcon-DC stable 
contacts.  IL-10 has been shown to down-regulate co-stimulatory molecules on DCs while IL-10 
neutralization had no effect on T cell activation in vitro, when T cells were stimulated with anti-
CD3 [43].  In addition, IL-10 deficiency or blockade had no effect on Treg-mediated suppression 
of T cell proliferation in vitro, when DCs were not present [28, 44].  Therefore, it is unlikely that 
IL-10 directly causes Tcons to decrease their interaction with DCs.  One hypothesis consistent 
with these data is that IL-10 down-regulates CD54 and CD86 on DCs, preventing Tcons from 
forming stable contacts with DCs (Suppl. Fig. 2.S5).  
 In summary, our findings shed new light on the activation of donor T cells by host APCs 
found after allogeneic stem cell transplantation.  In addition, we have found that eTregs and iTregs 
utilize a number of different approaches to block the activation of donor T cells by altering the 
early interaction between host APC and donor T cell.  
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Figure 2.1
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Figure 2.1: Donor T cells show decreased velocity, low displacement ratios, and early 
engagement with dendritic cells in lymph nodes 2 hours after transplant.  Intravital imaging 
of donor T cells (labeled with CMTPX) and host DCs in the popliteal LNs of irradiated or naïve 
CD11c-DTR-EGFP mice (BALB/c background). (a) Still images from the movies of 2hr, 8hr, 
19hr, and 24hr post-transplant.  Red cells are donor T cells and green cells are dendritic cells. (b) 
Instantaneous velocity of donor T cells 2 and 8 hours after transplant.  Median values are 
indicated by arrows.  Allogeneic (filled bar): donor T cells and BM cells from C57BL/6 mice.  
Syngeneic (open bar): donor T cells and BM cells from BALB/c mice.  Syngeneic-No 
conditioning (dashed bar): donor T cells from BALB/c mice transferred into naïve non-irradiated 
CD11c-DTR-EGFP mice. (c) Time course of mean velocity of donor T cells from 2-26 hours 
after transplant. (d) Displacement ratio (displacement/total track length of 30 minutes) of donor 
T cell movement from 2 hours to 26 hours after transplant. (e) Contact time between allogeneic 
donor T cells and host DCs at various time points post-transplant compared with syngeneic T 
cell controls. The red bars in all graphs represent median values. Asterisks (*) indicate 
statistically significant differences between two time points or conditions (p<0.05). Data are 
representative of three separate experiments, with one or two mice imaged per condition per 
experiment.  
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Figure 2.2
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Figure 2.2: The kinetics of T cell-DC interaction is similar in mice after chemotherapy or in 
BALB/c to CD11c-YFP mice. (a-c)  Intravital imaging of donor T cells (labeled with CMTPX) 
and host DCs in the popliteal LNs of CD11c-DTR-EGFP mice (BALB/c background) 
conditioned by chemotherapy (cyclophosphamide 200mg/kg i.p. one day before transplant). (a) 
Instantaneous velocity of Tcons at 2 hour and 8 hour post-transplant compared to Tcons in mice 
conditioned with irradiation. (b) Mean velocity of Tcons at various time points. (c) Contact time 
between donor Tcons and host DCs at various time points after chemo. (d-f)  Intravital imaging of 
BALB/c donor T cells (labeled) and host DCs in the LNs of CD11c-YFP mice (C57BL/6 
background). (d) Instantaneous velocity of Tcons at 2 hour and 8 hour post-transplant in YFP mice 
compared to those of CD11c-DTR-EGFP mice. (e) Mean velocity of Tcons in YFP mice. (f) 
Contact time between Tcons and DCs.  Each line represents a different time point. The bars in all 
graphs represent median values. Data are representative of two separate experiments, with one 
mouse imaged per condition per experiment. 
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Figure 2.3: eTregs show stable interactions with host DCs and interfere with the interaction 
between donor T cells and DCs in the lymph nodes. (a-c) Intravital imaging of donor T cells 
(labeled with CMTPX) and host DCs in the popliteal LNs of irradiated CD11c-DTR-EGFP mice 
in the presence (Tcon:Treg ratio of 3:2) or absence of unlabeled Tregs.  In the absence of Tregs, 
unlabeled T cells were injected to provide an identical number of donor cells. (a) The mean 
velocity of donor T cells in the presence or absence of eTregs from 4-24 hours post-transplant. (b) 
The time course of the displacement ratio of donor T cell movement in the presence or absence 
of eTregs. (c) Contact time between donor T cells and host DCs with or without eTregs at different 
Figure 2.3
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time points post-transplant. (d-g) Intravital imaging of donor eTregs (labeled with CMTPX) and 
host DCs in the presence of unlabeled Tcons. (d) Still image from movies of eTreg (red) with DCs 
(green). (e) Comparison of mean velocity between eTregs and Tcons cells at various time points 
after transplant. (f) Contact time between eTregs and host DCs, compared to contact time between 
donor T cells and DCs. (g) Comparison of mean velocity between eTregs and Tcons when they 
were injected into the same recipient.  The bars in all graphs represent median values. Asterisks 
(*) indicate statistically significant differences between time points (p<0.05) or p value is shown.  
Data are representative of two separate experiments with one mouse imaged per condition per 
experiment. 
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Figure 2.4: Inducible Tregs interfere with the interactions between donor T cells and host 
DCs comparable to eTregs. (a-c) Intravital imaging of donor T cells (labeled with CMPTX) and 
host DCs of irradiated CD11c-DTR-EGFP mice in the presence of eTregs (Tcon:eTreg ratio of 3:2) 
or inducible Tregs (Tcon:iTreg ratio of 1:1). (a) The time course of mean velocity of donor T cells in 
the presence of iTregs or eTregs. (b) The time course of the displacement ratio of donor T cell 
movement in the presence of iTregs or eTregs. (c) Contact time between donor T cells and DCs 
with iTregs or eTregs at 5 or 8 hours post-transplant. (d-f) Intravital imaging of donor iTregs or eTregs 
Figure 2.4
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(labeled with CMPTX) and host DCs in the presence of unlabeled donor T cells. (d) Still image 
from movies of iTreg (red) with DCs (green). (e) Comparison of mean velocity between iTregs and 
eTregs cells at various time points after transplant. (f) Contact time between iTreg-DC in 
comparison to contact time between eTregs and DCs at 2 different time points after transplant. 
The bars in all graphs represent median values. Asterisks (*) indicate statistically significant 
differences (p < 0.05) or p value is shown.  Data are representative of two experiments with 1-2 
mice per experiment.  
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Figure 2.5: IL-10 is required for Treg-mediated disruption of Tcon-DC interaction. Intravital 
imaging of donor T cells (labeled with CMTPX) and host DCs in the popliteal LNs of irradiated 
CD11c-DTR-EGFP mice in the presence of WT or of IL-10 -/- Tregs. (a) The comparison of mean 
velocity of donor T cells in the presence IL-10 -/- or WT Tregs. (b) The comparison of the 
displacement ratio of donor T cell movement in the presence IL-10 -/- or WT Tregs. (c) Contact 
time between donor T cells and host DCs in the presence IL-10 -/- or WT Tregs at different time 
points post-transplant. The bars in all graphs represent median values. Asterisks (*) indicate 
statistically significant differences between the groups or time points (p<0.05). Data are 
representative of two experiments with 1-2 mice per experiment. 
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Figure 2.6: Tregs down-regulate CD86 and CD54 on dendritic cells. Flow analysis on DCs 
from skin-draining lymph nodes (sLNs) and spleens of recipient mice that were transplanted with 
T cells or eTregs or iTregs (with TCD BM) one day or two days prior to analysis. Ctrl: antibody 
isotype control.  No HSCT/conditioning: mice were not irradiated or transplanted prior to 
evaluation.  BM: mice were transplanted with BM only.  W/ T: mice transplanted with donor T 
cells.  W/ e Treg: mice transplanted with endogenous Treg. W/ iTreg: mice transplanted with 
inducible Treg.  (a) The histogram of CD86 and CD54 expression on DCs from spleens of mice 
Figure 2.6
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transplanted with T cells or eTregs 2 days post-transplant. (b) The fold change of mean 
fluorescence intensity (MFI) for CD86 and CD54 on DCs was calculated by dividing the MFI of 
the specific staining antibody by the MFI of the control antibody. N = 3-4 mice per group (1 
mouse for no treatment) with representative data from 2 different experiments. (c) The histogram 
of CD86 and CD54 expression on DCs from sLNs of mice transplanted with T cells or iTregs one 
day post-transplant.  (d) MFI of CD86 and CD54 on DCs from (c). N = 3-4 mice per group (1 
mouse for no treatment) with representative data from 2 different experiments. No difference 
was found in the expression of CD80, CD40, MHCII, B7H3, B7H4 or CD70 on DCs in the 
presence or absence of eTregs  or iTregs (data not shown).  
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Figure 2.7. Tregs promote DC death. (a-e) Flow analysis on DCs from skin-draining lymph 
nodes (sLNs) and spleens of recipient mice that were transplanted with T cells or eTregs or iTregs 
(with TCD BM) one day or two days prior to analysis. (a) Total DC number on day 2 in the 
spleen of mice transplanted with T cells or eTregs on day 2 post-transplant. (b) Total number of 
DCs on day 1 in sLNs and spleen of mice transplanted with T cells or iTregs (c-e) The percentage 
of 7AAD+ DCs in total DCs from sLNs or the spleen of mice transplanted with T cells or eTregs 
Figure 2.7
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on day 1 (c) or day 2 (spleen only) (d). (e) The percentage of 7AAD+ DCs of total DCs from 
sLNs or spleens of mice transplanted with T cells or iTregs on day 1. (f) Flow analysis of eTregs 
from spleens three days post-transplant. N = 3-4 mice per group (1 mouse for controls) with 
representative data from 2 different experiments. 
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2.5 Supplementary Methods  
Mice 
 C57BL/6, BALB/c, IL-10-/-, CD11c-DTR-EGFP mice (on BALB/c background), and 
CD11c-YFP mice (on B6 background) were purchased from The Jackson Laboratory. Foxp3-
mRFP (FIR) mice were kindly provided by Dr. Yisong Wan.  All mice were maintained at the 
animal facility at The University of North Carolina in Chapel Hill.  All experiments were 
performed in accordance with protocols approved by The University of North Carolina 
Institutional Animal Care and Use Committee.  
 
Transplantation systems  
 Donor T cell-depleted (TCD) bone marrow (BM) cells were prepared as previously 
described [45]. CD25-deplected splenic T cells were prepared using negative selection of CD25-, 
CD19-, MHCII-, γδTCR-, CD11c-, CD11b-, CD49b-, and Ly6G--expressing cells by antibodies 
coupled to biotin and streptavidin-coupled ferromagnetic beads. Then the cells were purified 
through a magnetic activated cells sorter (MACS) column (Miltenyi Biotec).  T cell purity was 
measured by flow cytometry before transplantation and had 90-95% purity.  Recipient mice on 
BALB/c background were irradiated at 800 rads and B6 background mice at 950 rads one day 
prior to transplantation with 3-5 million of donor T cells (or 3 million total T cells with 2 million 
of Treg) and 4-5 million TCD BM cells. Donor WT or IL-10
-/- Treg cells were prepared as 
previously described using a column purification method [46].  Briefly, splenic T cells were 
purified through negative selection onto CD4 columns by Cedarlane.  These purified CD4+ T 
cells were stained with biotin-coupled anti-B220, anti-CD49b, anti-CD8, anti-γδTCR, and PE-
coupled CD25 and then negatively-selected using streptavidin Dynal beads and Dynal magnets 
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(Invitrogen).  Finally the cells were positively-selected using anti-PE microbeads through MACS 
column (Miltenyi).  The term eTregs is used to indicate the source of Treg cells that is used 
clinically realizing that this is composed of both natural and inducible Tregs with approximately 
70% of the eTregs expressing Helios suggestive but not conclusive for natural Tregs. 
 
Generation of inducible Tregs  
 CD4 T cells were purified from C57BL/6 lymph nodes and spleens using negative 
selection of CD25-, CD8-, CD19-, γδTCR-, and CD11b--expressing cells by MACS. CD25-CD4+ 
T cells were then cultured in a 24-well plate in DMEM containing 10% FBS, 1% L-glutamine, 
1% Pen-strep, 1% non essential amino acids, 10mM Hepes with 100 U/ml of IL-2 and 10 ng/ml 
of TGF-β for 4 days.  Purity of iTregs was greater than 85% (Suppl. Fig. 2d). 
 
Intravital imaging  
 CD11c-DTR-EGFP mice (BALB/c background) were lethally irradiated (800 cGy).  On 
the next day, they were transplanted with TCD BM cells, CMTPX (Invitrogen)-labeled naïve T 
cells and unlabeled naïve T cells from C57BL/6 mice.  In different experiment settings, the mice 
were transplanted with different combination of labeled T cells, labeled Tregs, or labeled iTregs 
with different unlabeled control cells.  The cell combinations are indicated in the figure legends. 
For some experiments, two hours after transfer, the recipient mice were injected with anti-
CD62L Ab (MEL- 14) to synchronize T cell movement in the LN [47].  At 2-8 and 18-24 hours 
after transplantation, recipient mice were anesthetized and the popliteal LN imaged using 
FV1000MPE microscope (Olympus).  The body temperature was maintained at 37 °C by an 
electric warm plate.  A plaster caste was put on a hind leg to minimize the respiratory 
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movements and microscopic surgery was done to expose the popliteal LN [48].  T cell-DC 
interactions in this LN were observed and XYZ/time-lapse movies were recorded.  The LN was 
excited at 860 nm.  5 z-planes separated by 3-5 µm were collected at 60 time points so that each 
movie was approximately 30-40 minutes.  Images were analyzed using Imaris and Matlab for 
velocity, cell interactions, cell confinement, and cell arrest. 
 
Flow cytometry of dendritic cells 
 Lymph nodes or spleen were minced in magnesium- and calcium-free Hank's balanced-
salt solution containing 5% FCS and 10 mM HEPES, pH 7.4 (Gibco), then were digested for 35 
min at 37 °C with collagenase A (1 mg/ml; Roche) and DNase I (0.2 mg/ml; Sigma-Aldrich).  
EDTA (final concentration, 20 mM) was added to the cells for 5 min at 25 °C.  Single-cell 
suspensions were prepared with 70 µm Cell Strainer nylon mesh (Falcon) and red blood cells 
were lyzed by ACK lysis buffer.  Cells were stained for 20 min at 4 °C with florescence-labeled 
antibodies in Dulbecco's PBS (Gibco) containing 3% FCS, 5 µg/ml of Fc block and 10 mM 
EDTA.  Flow cytometric acquisition was performed on a Cyan flow cytometer using Summit 
software (Dako) or LSRII using Diva software (BD).  αCD11c-APC.Cy7 (HL3), αCD54-APC 
(YN1/1.7.4), αCD86-FITC (GL1), αCD40-PE (1C10), αCD80-FITC(16- 10A1), αMHCII-ef450 
(AF6-120.1), and αCD70-PE (FR70) were either from eBioscience or BD pharmingen. 
 
Regulatory T cell suppression assay  
 BALB/c DCs used as stimulator cells for Tcon cell proliferation were prepared as 
previously described [49].  LN or spleen single cell suspensions were layered over RPMI-1640 
medium containing 10% (vol/vol) FCS and 17% (wt/vol) Nycodenz (Accurate Chemical and 
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Scientific) and centrifuged at 450g for 20 min at 25 °C.  Low-density cells at the interface were 
collected and washed.  DCs were then purified from these low-density cells by negative selection 
of CD3-, CD19-, Ly6G-, TER119-, γδTCR-, CD49b--expressing cells using MACS columns 
(Miltenyi).  C57BL/6 Tcons and Tregs were purified as described above.  Tcons were labeled with 
CFSE according to manufacturer’s instructions (Invitrogen).  DCs and Tcons were cultured at a 
1:5 ratio in 96-well round bottom plates with or without Tregs (1:1 ratio to Tcons) for 2-3 days. 
CFSE dilutions of Tcons were analyzed on MACSQuant (Miltenyi).  In some experiments, Tregs 
were labeled with CMTPX (Invitrogen) according to manufacturer’s instructions to evaluate the 
effect of CMTPX on Treg suppressor function. 
 
Statistical Analysis  
 All the comparisons between velocity, displacement ratio and contact time were tested by 
Mann-Whitney test using Prism software.  The differences between mean fluorescence intensity 
of DC molecules, numbers of DCs, and percentages of 7AAD+ DCs were compared by student’s 
t-test. P < 0.05 was considered significant. 
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Supplementary Figure 2.S1: Donor T cells display stable contacts with DCs from 2 hours 
post-transplant. Intravital imaging of donor T cells (labeled with CMTPX) and host DCs in the 
popliteal LNs of irradiated CD11c-DTR-EGFP mice (BALB/c background) or CD11c-YFP mice 
(C57BL/6 background). (a) Schematic plan for our experimental process. (b) CD11c-DTR-EGFP 
mice were irradiated before receiving red B6 donor T cells. This panel shows the percentage of 
remaining conjugates of Tcon-DC that last for 5, 10, 15, 20, 25, or 30 minutes. Each line 
represents a different time point post-transplant. (c) Percentage of remaining conjugates of Tcon-
DC that last for 5, 10, 15, 20, 25, and 30 minutes in CD11c-DTR-EGFP treated with cytoxan and 
transplanted with red T cells one day later. (d) Percentage of remaining conjugates of Tcon-DC 
that last for certain time in irradiated CD11c-YFP mice.  This is a BALB/c to C57Bl/6 model. 
Note: The percentage of remaining T-DC conjugates does not represent the frequency of 
allogeneic reactive T cells due to several reasons: (1) T cells in the imaging field (100-150 um 
below LN surface) may not be representative of all T cells infused. (2) There are a low level of 
non-specific long interaction between T-DC when DC are activated [47]. (3) CD11c promoter 
may also be activated in host T cells and macrophages. 
Supplementary Figure 2.S1
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Supplementary Figure 2.S2: Suppression of T cell proliferation by endogenous Tregs and 
inducible Tregs. (a, c, d) eTregs or iTregs were purified or generated according to the methods 
section and stained for CD4 first. Then intracellular FoxpP3 was stained by foxP3 staining kit 
according to manufacturer’s instructions (eBioscience). Single cell suspensions were analyzed by 
MACSQuant (Miltenyi). (a, c) T cells were cultured with allogeneic DCs (250,000 to 50,000 
DC) for 2 or 3 days in the presence or absence of eTregs or iTregs (250,000)(labeled with CMTPX 
or unlabeled). Whole culture was stained for CD4 or CD8 before analyzed on MACSQuant. 
CFSE dilutions of Tcons in the presence or absence of eTregs (b) or iTregs (e) are shown. 
Supplementary Figure 2.S2
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Supplementary Figure 2.S3: eTreg and iTreg disrupt Tcon-DC interaction while their own 
interactions with DC are not affected by Tcon. Intravital imaging of donor T cells or eTreg or 
iTreg (labeled with CMTPX) and host DCs in the popliteal LNs of irradiated CD11c-DTR-EGFP 
mice. (a) Percentage of remaining conjugates of Tcon-DC that last for 5, 10, 15, 20, 25, and 30 
minutes with or without Tregs (unlabeled). Each line represents different time points or 
conditions. (b) Percentage of remaining conjugates of eTreg-DC that last for certain time in 
Supplementary Figure 2.S3
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comparison to conjugates of Tcon-DC. (eTreg imaging was accompanied by unlabeled Tcon in 
order to keep consistent cell number.) (c) Percentage of remaining conjugates of Tcon-DC that 
last for 5, 10, 15, 20, 25, and 30 minutes in the presence of iTregs or eTregs (unlabeled). (d) 
Percentage of remaining conjugates of iTreg-DC that last for certain time in comparison to 
conjugates of eTreg-DC. (e) Percentage of remaining conjugates of Tcon-DC that last for 5, 10, 15, 
20, 25, and 30 minutes in the presence of IL-10-/- or WT eTregs (unlabeled). 
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Supplementary Figure 2.S4: iTregs also express FasL. Flow analysis of iTregs that were 
generated from CD4+CD25- spleen cells in culture for four days. iTregs are gated on CD4+FoxP3+ 
while CD4+FoxP3- cells were used for comparison. The expression of granzyme B, perforin, and 
FasL are shown. Ctrl: Ab isotype control on total CD4+ cells.  
Supplementary Figure 2.S4
 75 
 
Supplementary Figure 2.S5: DC:T cell interactions within the lymph node following 
allogeneic transplantation. During the early phase (4-12 hours) following T cell transfer (far 
left panel), donor conventional T cells (Tcon), endogenous regulatory T cells (eTreg), and induced 
Treg (iTreg) enter the lymph node from the circulation and engage recipient dendritic cells (DC) 
expressing major histocompatibility-peptide complexes (MHC), costimulatory molecules such as 
CD40, and adhesion molecules such as CD54. Both eTreg and iTreg exhibit superior DC 
engagement in comparison to Tcon. By 18-24 hours after transfer (middle panel), donor T cells 
start disengaging from DCs and increase their migratory velocity. Stimulated Tcon undergo 
proliferation and upregulation of activation markers, while eTreg and iTreg induce DC death. After 
48 hours (far right panel), eTreg and iTreg induce loss of costimulatory and adhesion molecules 
from the DC plasma membrane.  
Supplementary Figure 2.S5
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CHAPTER THREE 
ALTERED T-CELL ENTRY AND EGRESS IN THE ABSENCE OF CORONIN 1A 
ATTENUATES MURINE ACUTE GRAFT VERSUS HOST DISEASE2 
 
3.1 Introduction 
Acute graft-versus-host disease (aGvHD), a disease of selective epithelial damage, is a 
severe complication of allogeneic stem cell transplantation (SCT).  aGvHD occurs when mature 
donor T cells recognize host alloantigen and initiate an immune response [1].  Work from our 
group and others has shown that prior to tissue destruction, donor T cells must migrate to 
secondary lymphoid tissue (SLT) where they are activated by host antigen presenting cells 
(APCs) [2, 3].  Upon activation, donor T cells migrate to target organs, primarily the liver, 
gastrointestinal tract, skin, and lung, where they cause tissue damage and destruction 
characteristic of aGvHD [4].  
The migration of lymphocytes to target organs involves selectins, integrins, and small 
chemotactic proteins known as chemokines [5].  Chemokines bind G-protein coupled chemokine 
receptors, which direct the migration of lymphocytes to target locations.  Our group has  
                                                
2 This work is in press in the European Journal of Immunology, published ahead of print as: 
Fulton, LM*, Taylor NA*, Coghill JM, West ML, Föger N, Bear JE, Baldwin AS, Panoskaltsis-
Mortari A, Serody JS. Altered T-Cell entry and egress in the absence of Coronin 1A attenuates 
murine acute graft versus host disease. Eur J Immunol; 2014. © John Wiley and Sons. 
 
* These authors contributed equally to this work. 
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demonstrated the importance of migration of donor T cells and their interaction with APCs in 
GvHD pathogenesis [6].  Furthermore the importance of SLT in GvHD pathogenesis has been 
demonstrated, as animals lacking all SLT, including the spleen, display markedly attenuated 
GvHD [3, 7].  However, despite multiple attempts, we have not been successful in completely 
preventing aGvHD by blocking proteins important for T-cell migration. 
Numerous biological processes are regulated by the actin cytoskeleton and its associated 
proteins.  The Coronin family of actin-associated proteins has been shown to be involved in cell 
migration, motility, and cell survival [8].  Coronins bind F-actin and interact with the Arp2/3 
complex [9], where they are critical in preventing nucleation of the branched F-actin chain.  
Coronin 1A (Coro 1A) was the first of the seven family members identified.  Coro 1A is 
expressed primarily in hematopoietic cells and co-localizes with F-actin [10].  Expression of 
Coro 1A in T lymphocytes is important for cytoskeleton rearrangement [11-13].  Several groups 
have evaluated the function of immune cells from mice lacking Coro 1A.  These studies have 
indicated that T cells from Coro 1A knockout mice do not function normally, although the 
mechanisms for this finding are still somewhat unclear and focus either on proximal signaling 
events after activation of the T-cell receptor, and/or the induction of apoptosis due to impaired 
generation of F-actin [12, 13].  In addition, a third group evaluated the migration of thymocytes 
using mice with a point mutation in Coro 1A that led to hypomorphic function for Coro 1A.  
They demonstrated impaired migration of thymocytes from these mice in response to the 
signaling lipid sphingosine 1 phosphate, leading to impaired thymic egress [14]. 
Reorganization of the actin cytoskeleton is an early response to chemokine receptor 
stimulation [15].  Chemokine receptors have been shown to regulate signaling molecules that are 
important for regulation of chemotaxis in lymphocytes and other cells [15-17].  Interestingly, the 
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transcription factor nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) has 
been shown to be involved in the interaction between activation of T cells and cytoskeleton 
alterations for mobility [18].  However, the mechanisms by which these processes are linked 
remain unclear.  
Currently, while multiple investigators have indicated that the complete absence of SLT 
including the spleen eliminated aGvHD, it is not clear if aGvHD would be impacted by the 
inability of donor T cells to egress from SLT.  Previous work suggesting that the absence of Coro 
1A led to impaired migration led us to investigate the biology of aGvHD in a system where T 
cells were impaired in their ability to enter or exit SLT.  Here we show that unlike our 
approaches targeting specific chemokine receptors, aGvHD is completely eliminated by the 
inability of donor T cells to exit SLT and migrate to aGvHD target organs.  These alterations in 
migration of Coro 1A deficient cells were mediated by decreased expression of the migratory 
proteins S1Pr1 and CCR7.  
 
3.2 Materials and Methods 
Mice 
 C57BL/6J (H2b) (termed WT), BALB/c, and C57BL/6J x DBA/2 F1 (termed B6D2) were 
purchased from The Jackson Laboratory.  The generation of enhanced green fluorescent protein 
expressing (GFP) C57BL/6 mice has been described previously [4].  Coro 1A deficient (Coro 
1A-/-) C57BL/6 mice were obtained from Niko Foger and generated as described [12-34].  Coro 
1A-/- GFP mice were generated by crossing Coro 1A-/- mice with GFP C57BL/6 mice.  All 
experiments were performed in accordance with protocols approved by the University of North 
Carolina Institutional Animal Care and Use Committee. 
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Transplantation Models 
 T cell depleted bone marrow (TCD BM) was prepared as previously described [35].  
CD25 depleted T cells were prepared using a total T cell isolation kit (Cedarlane Laboratories) 
followed by antibody depletion and magnetic cell separation as previously described [3].  The 
day prior to transplantation, recipient mice received either 950 cGy (B6D2) or 800 cGy 
(BALB/c) of total body irradiation.  For B6 to B6D2 or B6 to BALB/c transplants, recipients 
were intravenously injected with either 4 x 106 T cells and 3 x 106 TCD BM cells, or 5 x 105 total 
T cells and 5 x 106 TCD BM cells, respectively, unless otherwise noted.  Histopathology 
analyses were prepared as previously described and analyzed by one of us (A.P.M.) blinded to 
the genotype of the donor [36]. 
  
Stereomicroscopy 
 Organs from anesthetized animals were imaged with a Zeiss Stereo Lumar V12 
microscope with GFP bandpass filter (Carl Zeiss MicroImaging, Inc.) at room temperature.  
AxioVision (Carl Zeiss) software was used to determine GFP intensities.  WT GFP and Coro 1A-
/- GFP recipient organs were imaged using the identical magnification (mag) and exposure (exp) 
times for each time point.  Day +3: PP-exp 976ms, mag 32X MLN-exp 2.5s, mag 15X Day +14: 
PP-exp 1s, mag 30X MLN-exp 1s, mag 20X Colon-exp 4s, mag 13X Liver-exp 2s, mag 40X 
Lung-exp 4s, mag 18X Day +28: PP-exp 750ms, mag 30X MLN 600ms, mag 20X Colon-exp 3s, 
mag 13X Liver-exp 3s, mag 40X 
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Organ GFP Quantification 
 Organs from recipient animals were homogenized and absolute GFP levels determined by 
ELISA (Cell Biolabs).  Detailed experimental procedures were conducted as described 
previously [3]. 
 
In Vivo Competitive Migration Assay 
 CD25 negative total T cells were isolated as described above from Coro 1A-/- GFP and 
Thy 1.1+ WT mice.  Recipient B6D2 mice were injected intravenously with equal amounts of 
Coro 1A-/- GFP and WT Thy 1.1+ donor T cells.  16 hours post transplantation, the mesenteric 
lymph node, inguinal lymph node, and spleen were harvested, stained, and analyzed by flow 
cytometry. 
 
Real Time PCR Analysis 
 Real time PCR was performed as previously described [36].  Gene expression was 
normalized to the housekeeping gene GusB before determining fold induction using ΔΔCt 
method.  Taqman expression assay probes for S1Pr1, S1Pr3, S1Pr5, and CCR7 were purchased 
from Applied Biosystems. 
 
Chemotaxis Analysis 
 Conventional T cells (Tcon cells) were isolated using Cedarlane total T cell isolation kit 
following by antibody depletion coupled with negative selection.  Following isolation the cells 
were washed twice with PBS.  5 x 105 or 2 x 105 total T cells in 100µL were added to the upper 
chamber of a PVP treated 5µM pore polycarbonate membrane inside of a ChemoTx® chamber 
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system (Neuroprobe).  The bottom chamber was filled with the indicated concentrations of 
sphingosine-1 phosphate (Sigma) or C-C motif chemokine 19 (Peprotech) and incubated for 3 
hours at 37oC.  CyQuant cell quantification kit (Invitrogen) was used to determine cell migration 
from the upper chamber to the lower chamber. 
 
Western Blot Analysis 
 Freshly isolated Tcon cells were lysed in RIPA (Invitrogen) buffer supplemented with 
protease and phosphatase inhibitors (Roche).  Lysates were separated by SDS-PAGE on a 4-12% 
Bis-Tris gel (Life Technologies), transferred onto a nitrocellulose membrane and incubated in 
5% non-fat dry milk to block non-specific binding.  Membranes were incubated with the 
following antibodies purchased from Cell Signaling Technology: phospho NF-κB p65 (Ser536), 
NF-κB2 p100/p52.  GAPDH antibody was purchased from Santa Cruz Biotechnology.  Proteins 
were detected using anti-rabbit IgG HRP (Promega) and the ECL western blotting detection kit 
according to manufacturer’s instructions (GE Healthcare). 
 
In Vivo Proliferation 
 Lethally irradiated B6D2 recipients were transplanted with equal amounts of Coro 1A-/- 
GFP and WT Thy 1.1+ donor total T cells concurrently with WT TCD BM.  Ten days post 
transplantation recipient mice were injected intraperitoneally with BrdU labeling reagent 
(Invitrogen).  Four hours after injection the spleens were harvested and stained for BrdU 
(Invitrogen) and the following antibodies from eBioscience: CD45, CD44, CD62L, Thy 1.1.  
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Mixed Lymphocyte Reaction 
 Equal amounts of Coro 1A-/- or WT T cells and irradiated B6D2 splenocytes were 
cultured in RPMI complete for 24 or 48 hours. For activation the cells were stained with the 
following antibodies from eBioscience: CD62L, CD44, CD69. For cytokine production the cells 
were permeabilized using the BD Cytofix/cytoperm plus kit and stained with TNF or IFN-γ 
antibodies also purchased from eBioscience. Cells were analyzed by flow cytometry using 
FlowJo analysis software. 
 
Proliferation Assay 
 Coro 1A-/- or WT T cells were labeled with 10µM carboxyfluorescein succinimidyl ester 
(CFSE) (Invitrogen). Equal amounts of labeled Coro 1A-/- or WT Teffs and B6D2 irradiated 
splenocytes were cultured in RPMI complete for 24 or 48 hours. Following harvest the cells were 
stained with CD4 and CD8 antibodies (eBioscience). Proliferation was determined by flow 
cytometry using the FlowJo analysis software.  
 
GvHD Scoring 
 Mice were observed twice weekly for clinical GvHD signs and symptoms based on a 
previously established clinical scoring system [37]. 
 
Statistical Analysis 
 Survival curves were constructed using the Kaplan Meier method.  Median survival was 
determined using the log rank test.  Continuous values including cytokine levels, total cell 
numbers, clinical scoring and GFP expression were determined using two-tailed Student’s t-test.  
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P-values less than 0.05 were considered significant.  Error bars represent standard error of the 
mean. 
 
3.3 Results 
Attenuated GvHD in multiple mouse models using Coro 1A-/- T Cells  
The expression of Coronin 1A (Coro 1A) has been shown to be important for T cell 
trafficking [13]; however, the contribution of Coro 1A to disease pathophysiology remains 
unclear [14].  To address the importance of Coro 1A in aGvHD, conventional T cells (Tcon) cells 
from Coro 1A-/- or C57BL/6 (WT) donors supplemented with WT T cell depleted bone marrow 
(TCD BM) cells were transplanted into lethally irradiated B6D2 F1 recipients.  As shown in 
Figure 3.1A, recipients of Coro 1A-/- Tcon cells had significantly improved survival compared to 
recipients of WT donor Tcon cells.  The clinical GvHD scores confirmed survival data, 
demonstrating decreased clinical symptoms in recipients of Coro 1A-/- Tcon cells compared with 
WT Tcon cells recipients (Fig 3.1A).  Recipients of Coro 1A-/- Tcon cells were fully donor by 
chimerism analysis by day 24 post-transplantation (data not shown). 
We further evaluated the importance of Coro 1A in aGvHD using a complete mismatch 
(B6 into BALB/c) transplant model.  Previously, we were not able to completely prevent the 
development of aGvHD targeting chemokine ligands or receptors using this model.  Lethally 
irradiated BALB/c recipients were administered Tcon cells from Coro 1A-/- or WT donors with 
WT TCD BM.  Similar to the haploidentical model, recipients of Coro 1A-/- Tcon cells showed 
100% survival until day 60 with minimal clinical manifestations of GvHD (Fig 3.1B).  
Histopathology analysis of aGvHD target organs revealed decreased pathology in Coro 1A-/- 
recipients compared to WT recipients (Fig 3.2) with significant differences in the liver and 
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spleen and a trend for decreased pathology in the colon.  Coro 1A-/- Tcon cells recipients also 
displayed decreased organ cytokine production on day 14 with the values for IFN-γ production in 
the liver and TNF and IFN-γ in the spleen being statistically significant (Supplementary Fig 
3.S1).  Thus, the absence of Coro 1A from donor T cells led to a profound decrease in the 
generation of aGvHD, even across a complete MHC mismatch. 
Previous work suggested two potential mechanisms for diminished aGvHD in the 
absence of Coro 1A.  T cells deficient in Coro 1A may be impaired in activation mediated by 
engagement of the T-cell receptor [12], or Coro 1A-/- T cells may be impaired in the ability to 
migrate in and out of lymphoid tissue [14]. Using cell proliferation dye or Brdu and cell surface 
markers for activation, we evaluated these potential mechanisms in the post-transplant setting at 
both day 3 and day 10 post-transplant.  On day 3 post-transplant, there was decreased 
proliferation of Coro 1A-/- Tcon cells in the spleen compared to WT Tcon cells (Supplementary Fig 
3.S2A).  However, both CD4+ and CD8+ Coro 1A-/- T cells exhibited increased CD69 expression, 
the earliest marker of T-cell activation.  Other activation markers were more varied, with 
increased CD62L expression by Coro 1A-/- CD4+ T cells, but decreased CD62L expression of 
Coro 1A-/- CD8+ T cells.  No differences were found in CD25 or ICOS expression of CD4+ Tcon 
cells lacking Coro 1A.  However, there was decreased expression of CD25 and ICOS in Coro 
1A-/- CD8+ Tcon cells on day 3 post transplant.  On day 10 post-transplant, there was no difference 
in the proliferation of donor WT versus Coro 1A-/- T cells isolated from the spleens of B6D2 
recipients (Supplementary Fig 3.S2B).  To determine if the differences in activation markers 
were due to intrinsic differences in T cell activation, we evaluated T-cell activation and 
proliferation in vitro. Proliferation, measured by loss of carboxyfluorescein succinimidyl ester 
(CFSE) and the generation of IFN-γ by T cells, was equivalent in WT and Coro 1A-/- Tcon cells 
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(data not shown).  Thus, intrinsically, there was no difference in the activation or proliferation of 
WT or Coro 1A-/- T cells. 
 
Coro 1A-/- T Cells accumulate in gastrointestinal tract lymph nodes 
Donor T cell activation requires the migration of donor cells into the spleen and 
secondary lymphoid tissue of the host.  One hypothesis for the inability to activate donor T cells 
from Coro 1A null donors is the inability of those cells to migrate to SLT.  To determine if 
migration defects contributed to attenuated aGvHD using Coro 1A-/- donor T cells, we crossed 
Coro 1A-/- mice with mice that constitutively express enhanced green fluorescent protein (GFP). 
Using Coro 1A-/- GFP and WT GFP mice as donors, lethally irradiated B6D2 F1 recipients were 
administered Tcon cells with WT (non-GFP) TCD BM.  Three days post-transplant, the MLN and 
PP were imaged by stereomicroscopy.  Increased GFP expression in the MLN was seen in WT 
GFP recipients as compared to Coro 1A-/- GFP recipients, suggesting a delay in entry into lymph 
nodes by Coro 1A-/- T cells (Fig 3.3A).  Surprisingly, accumulation of Coro 1A-/- T cells was 
seen in the MLN and PP of B6D2 recipients 14 days post-transplantation, which continued 
through 28 days post-transplantation (Fig 3.3A).  Consistent with the accumulation seen in the 
MLN and PP, there was a decrease in donor T cells in the liver and colon of Coro 1A-/- T cells as 
measured by stereomicroscopy and GFP ELISA (Fig 3.3A and 3.3B).  Migration defects 
displayed by microscopy were complemented by blood analysis on day 14 post-transplantation 
that revealed a decrease in circulating T cells in B6D2 recipients given T cells from Coro 1A-/- 
GFP donors compared to WT GFP donors (Fig 3.3C).  These data were consistent with impaired 
entry and egress out of lymph nodes by Coro 1A-/- T cells.  
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To further confirm a defect in entry and egress from SLT, we performed an in vivo 
competitive migration assay.  Equal amounts of Coro 1A-/- GFP and WT Thy 1.1+ T cells were 
injected into lethally irradiated B6D2 F1 recipients.  16 hours post-transplantation, the MLN and 
inguinal lymph nodes (ILN) were harvested and analyzed by flow cytometry.  As demonstrated 
in Figure 3.3D, even at this early time point, Coro 1A-/- T cells were markedly less efficient in 
entering the MLN and ILN, as compared to WT T cells. 
 
Decreased SLT ingress and egress receptors in Coro 1A-/- T cells 
 Numerous researchers have shown that the C-C chemokines receptor type 7 (CCR7) is 
important for entry of T cells into secondary lymphoid organs [19].  Furthermore, data from our 
laboratory have highlighted the importance of CCR7 in migration and GvHD pathogenesis [3].  
As Coro 1A-/- T cells displayed defects in lymph node entry, we questioned whether Coro 1A-/- T 
cells had decreased CCR7 expression.  To address this question, real time PCR analysis was 
performed on freshly isolated Coro 1A-/- and WT Tcon cells.  Surprisingly, Coro 1A-/- Tcon cells 
expressed 2-fold less CCR7 than WT T cells (Fig 3.4A).  This decrease in CCR7 was further 
confirmed using an in vitro chemotaxis assay to the CCR7 ligand, CCL19.  Similar to the real 
time data results, Coro 1A-/- T cells displayed impaired migration to CCL19 (Fig 3.4A).  
Responsiveness of Coro 1A-/- T cells to a chemoattractant was confirmed using the supernatant 
from stimulated allogeneic dendritic cells (Supplementary Fig 3.S2C). 
 In addition to the impaired migration into SLT, Coro 1A deficient T cells were unable to 
egress from lymphoid tissue compared to WT T cells.  Sphingosine-1 phosphate (S1P) is a 
signaling sphingolipid that is produced by hematopoietic cells that has been shown to be 
important for immune cell egress from SLT.  Of the 5 S1P receptors, S1Pr1 has been shown to 
 91 
be important for lymphocyte egress [20].  To evaluate S1P receptor expression in Coro 1A-/- T 
cells, we used quantitative real time PCR analysis.  Coro 1A-/- Tcon cells displayed decreased 
S1Pr1 expression compared to WT Tcon cells (Fig 3.4B).  However, no difference was found in 
the expression of the other S1P receptors (Fig 3.4B and data not shown) on Coro 1A deficient T 
cells.  Additionally, we demonstrated a marked impairment in the migration of Coro 1A-/- T cells 
to S1P compared to WT T cells indicating that this difference in expression led to functional 
differences in response to the ligand (Fig 3.4B).  These data indicate that decreased CCR7 and 
S1Pr1 expression on Coro 1A-/- T cells correlated with the decreased migration into and out of 
lymphoid organs. 
 
Disruption of the NF-κB Pathway in the absence of Coro 1A 
To investigate the mechanism for the diminished expression of CCR7 and S1Pr1 by Coro 
1A-/- T cells, we analyzed signaling pathways in conventional T cells.  Regulation of the integrity 
of the actin cytoskeleton is important for numerous signaling pathways including the NF-κB and 
the mitogen-activated protein kinase (MAPK) pathways [21-22].  Decreased phosphorylated p65 
was found under stimulating and non-stimulating conditions in Coro 1A-/- Tcon cells (Fig 3.5).  
Alterations in the NF-κB pathway were specific to the canonical pathway, as no changes in the 
p100 subunit were observed in WT or Coro 1A-/- Tcon cells (Fig 3.5).  We found no difference in 
activation under stimulating or non-stimulating conditions of the p38 MAPK protein in Coro 1A 
null compared to WT T cells as evaluated by western blot (Supplementary Fig 3.S3).  These data 
suggest that the expression of CCR7 and S1P1r in Coro 1A-/- Tcon cells are correlated with 
impaired activation of the canonical NF-κB pathway [23]. 
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Maintenance of the GvL response using Coro 1A-/- Tcon cells 
 T cells responsible for the pathogenesis of aGvHD are also responsible for the graft-
versus-leukemia effect (GvL) that eliminates residual tumor cells in recipients minimizing the 
probability of relapse.  Knowingly, we investigated whether Coro 1A-/- Tcon cells maintain GvL 
effects.  WT TCD BM with luciferase expressing A20 B cell lymphoma cells were transplanted 
into lethally irradiated B6D2 F1 recipients with either Coro 1A-/- Tcon cells or WT Tcon cells.  
B6D2 recipients of Coro 1A-/- T cells survived until completion of the experiment with no tumor 
infiltration, while B6D2 recipients given A20 cells with bone marrow alone succumbed to death 
by tumor infiltration 24 days post-transplantation (Fig 3.6).  Mice that received WT Tcon cells 
succumbed to death by aGvHD, prior to infiltration of tumor cells (data not shown).  These data 
demonstrate that in addition to attenuated aGvHD, Coro 1A-/- Tcon cells maintained the beneficial 
GvL response. 
 
3.4 Discussion 
 The contribution of T-cell migration to aGvHD pathogenesis has been well studied [3, 
24].  Our group and others have shown that chemokines and their receptors, integrins, and 
selectins all play a critical role in T cell migration during aGvHD [6, 25, 26].  Here we extend 
these findings, demonstrating that cells deficient in the F-actin associating protein, Coronin 1A, 
are markedly impaired in their ability to mediate acute GvHD due to accumulation in secondary 
lymphoid organs and the inability to egress from these organs.  The diminished aGvHD seen 
using T cells deficient in Coro 1A correlated with decreased tissue pathology in recipient mice.  
In vitro proliferation and cytokine production by Coro 1A-/- Tcon cells was comparable to WT 
Tcon cells; while decreased proliferation by Coro 1A-/- Tcon cells was seen in vivo and markers of 
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early activation were comparable to that of WT Tcon cells.  Lastly, we showed that signaling 
cascades downstream of the TCR are impaired in the absence of Coro 1A.  The reduction in the 
expression and function of CCR7 and S1Pr1 correlated with impaired migration and activation of 
the canonical NF-κB pathway.  Thus, these data suggest that one method of blocking acute 
GvHD is to prevent the migration of donor lymphocytes into and out of SLT. 
 The function of SLT in the biology of aGvHD has been studied elegantly by several 
different investigators predominately using genetic approaches.  These data indicated that SLT 
was critical to the induction of acute GvHD [7, 27].  However, this activity was redundant, with 
all secondary lymphoid tissue and the spleen capable of initiating acute GvHD.  Thus, it has not 
been clear if this process would be amenable to clinical intervention.  Here, we show that acute 
GvHD can be prevented by blocking the migration of T cells into and out of secondary lymphoid 
tissue, which correlated with the impaired function of CCR7 and S1P1r.  Clinically this is 
important as both CCR7 and S1Pr1 are drugable targets.  S1P agonists are currently available for 
the treatment of patients with multiple sclerosis [28].  Our group has initiated a significant 
screening process to identify inhibitors of CCR7.  Our data would suggest that a combination 
approach using these inhibitors would have significant activity in preventing acute GvHD.   
Several laboratories, but most specifically the Cyster laboratory, have shown in a number 
of elegant manuscripts the requirement for S1Pr1 expression on T cells for migration of those 
cells out of lymph nodes via the efferent lymph system [29].  The function of S1Pr1 is not 
limited to lymphocyte migration, as S1Pr1 has also been shown to be important in inflammatory 
responses in other immune cells [30].  Real time PCR analysis of Coro 1A-/- T cells confirmed 
decreased expression of S1Pr1 but not other S1P receptors on Coro 1A-/- T cells.  Interestingly, 
our group has previously evaluated the function of FTY720, an agonist of S1P that, in models, 
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prevents acute GvHD pathogenesis [31].  While we were able to indicate that FTY720 
administration could abrogate acute GvHD, this did not correlate with impaired egress of donor 
T cells from SLT.  Thus, the current data are the first to indicate that egress out of SLT is 
important for the function of donor T cells during acute GvHD [32].  
 The importance of the chemokine receptor CCR7 in T lymphocyte migration has been 
well established.  Data from our group demonstrated impaired donor T cell migration to 
secondary lymphoid organs of donor T cells lacking CCR7 [3].  However, in our previous work, 
we were unable to completely block acute GvHD in the major mismatch model by infusing T 
cells lacking CCR7.  This indicates that the profound decrease in aGvHD found after the infusion 
of T cells lacking Coro 1A in BALB/c recipients is not solely due to the absence of CCR7.  This 
would further suggest that blocking migration into and out of secondary lymphoid tissue has a 
more profound effect than blocking the initial interaction of donor T cells with APCs.   
 Blocking of GvHD that mitigates the GvL response is not a successful strategy for 
improving allogeneic SCT.  Tumor cell elimination was seen in Coro 1A-/- Tcon cells recipients, 
demonstrating maintenance of GvL response by Coro 1A-/- Tcon cells in a lymphoma model.  
Importantly mice that received WT Tcon cells with tumor cells succumbed to aGvHD before 
tumor infiltration could occur.  These results further highlight the benefits of Coro 1A-/- Tcon cells 
in allogeneic SCT.  It should be noted that naïve T cells deficient in Coro 1A may have a reduced 
anti-leukemic response due to a decreased ability to exit SLT and traffic to the bone marrow.  
However previous investigations have found that antigen-specific T cells that traffic to the bone 
marrow can be primed by bone marrow resident DCs [33].  This priming, even in the absence of 
secondary lymphoid tissue, generates cytotoxic T cells that can provide an anti-tumor response 
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and immunologic memory.  Thus, we believe that blocking the migration of naïve T cells in and 
out of SLT may not hinder the activation of antigen-specific T cells in the bone marrow.   
 In summary, we have found that the absence of Coro 1A in donor T cells markedly 
diminished the incidence and severity of acute GvHD.  We demonstrate that Coro 1A-/- T cells 
have impaired migration into and out of secondary lymphoid tissue, which correlated with 
diminished expression of CCR7 and S1P1r.  These data indicate that approaches that prevent the 
migration of T cells into and out of secondary lymphoid tissue with maintenance of GvL 
response may significantly impact the occurrence of acute GvHD.  
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Figure 3.1: Attenuated GvHD in the absence of Coro 1A. (A) 4 x 106 Coro 1A-/- T cells (Tcon 
cells) or WT Tcon cells supplemented with 3 x 106 WT T cell depleted bone marrow cells (TCD 
BM) were injected into lethally irradiated B6D2 recipients. Recipients were then monitored for 
survival (left) and GvHD score (right).  Data are shown as mean + SEM of n=14 for Coro 1A-/- 
and WT Tcon cells recipients, n=4 for bone marrow only. Data are pooled from 3 individual 
experiments. (B) Lethally irradiated BALB/c recipients were infused with 5 x 105 Coro 1A-/- or 
WT Tcon cells with 5 x 106 WT TCD BM cells. Following transplantation mice were monitored 
for survival (left) and clinical GvHD development (right). Data are shown as mean + SEM of 
n=19 for Coro 1A-/- and WT Tcon cells recipients, n=6 for bone marrow only. Data are pooled 
from 3 individual experiments. *p<0.001, two tailed Student’s t-test.  
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Figure 3.2: Histopathology of B6D2 recipients after transplantation of Coro 1A-/- or WT 
Tcon cells. Lethally irradiated B6D2 recipients were transplanted with 4 x 106 Coro 1A-/- or WT 
Tcon cells with 3 x 106 WT TCD BM. Fourteen days post transplantation organs were harvested 
for pathology analyses. Data are shown as mean + SEM of n=6 for Coro 1A-/- and WT recipients, 
n=4 for bone marrow controls, from a single experiment representative of 2 performed. *p<0.05, 
two tailed Student’s t-test. 
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Figure 3.3: Delayed entry and impaired egress in secondary lymphoid organs by Coro 1A-/- 
Tcon cells. Coro 1A-/- GFP or WT GFP Tcon cells supplemented with WT TCD BM were infused 
into lethally irradiated B6D2 recipients. (A) Migration of the cells to the liver, colon, mesenteric 
lymph node and Peyer’s patches was determined using stereomicroscopy. Images were collected 
3, 14 and 28 days post transplantation. Left panels display GFP expression while right panels 
reflect intensity. Data shown are representative of 6-8 B6D2 recipients given either Coro 1A-/- 
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GFP or WT GFP Tcon cells. (B) GFP ELISA was used to quantify expression in B6D2 recipients 
transplanted with Coro 1A-/- GFP or WT GFP Tcon cells 14 days post transplantation. Data shown 
are mean + SEM of n=5 for WT GFP and Coro 1A-/- GFP recipients from a single experiment 
representative of 3 experiments performed. *p<0.05, two tailed Student’s t-test. (C) Peripheral 
blood was collected from WT GFP or Coro 1A-/- GFP Tcon cells recipients 14 days post 
transplantation. T cells in the blood were evaluated by flow cytometry using CD4 and CD8 
surface markers.  Cells were gated first by GFP positive expression then CD4 and CD8 
expression. Data are shown as n=4 for Coro 1A-/- GFP recipients, n=3 for WT GFP recipients 
from a single experiment. (D) In vivo competitive migration using Coro 1A-/- GFP and WT (Thy 
1.1+) cells was performed as detailed in Materials and Methods. Flow cytometry analysis of 
Coro 1A-/- GFP and WT (Thy 1.1+) Tcon cells were conducted on the spleen (data not shown) and 
pooled mesenteric and inguinal lymph nodes (representative sample shown) 16 hours post 
transplantation. Data shown are representative of n=3 for Coro 1A-/- GFP or WT (Thy 1.1+) Tcon 
cells recipients, from an experiment performed twice. 
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Figure 3.4: Decreased receptor expression and impaired chemotaxis in the absence of Coro 
1A. (A) Expression of CCR7 and chemotaxis to CCL19 of WT or Coro 1A-/- Tcon cells was 
determined by real-time PCR. (B) Real time expression of S1Pr1 and S1Pr5 and chemotaxis to 
S1P in WT and Coro 1A-/- Tcon cells is also shown. *p<0.05, two tailed Student’s t-test. Data are 
shown as mean + SEM of three experiments of n=9 WT and n=9 Coro 1A-/- Tcon cells. 
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Figure 3.5: Decreased activation of NF-κB in Coro 1A-/- Tcon cells. 3 x 106 WT or Coro 1A-/- 
Tcon cells were stimulated for 30 minutes with either 20ng/mL of TNF or 20ng/mL of anti-CD3 
and 10ng/mL of anti-CD28. Tcon cells were harvested and analyzed by western blot for p100 and 
phospho p65 expression. GAPDH was used as a loading control.  Data shown are representative 
of 3 individual experiments. 
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Figure 3.6: GvL response using Coro 1A-/- Tcon cells. 1 x 104 luciferase-expressing A20 B cell 
lymphoma cells supplemented with WT TCD BM were injected into lethally irradiated B6D2 
recipients. Mice were also injected with either Coro 1A-/- or WT Tcon cells. Mice were monitored 
for survival and tumor infiltration via luciferase imaging using the IVIS® Kinetic Optical System. 
Data shown are representative of n=12 for Coro 1A-/- and n=9 for A20 + bone marrow. Data are 
pooled from three individual experiments. 
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Supplementary Figure 3.S1: Cytokine production, proliferation, and chemotaxis of Coro 
1A-/- T-cells. Lethally irradiated B6D2 recipients were injected with Tcon cells from Coro 1A-/- or 
WT donors supplemented with WT TCD BM.  Fourteen days post transplantation, animals were 
perfused and organs were harvested and homogenized for cytokine production by ELISA. n=5 
for Coro 1A-/- or WT.  
Supplementary Figure 3.S1
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Supplementary Figure 3.S2: Decreased proliferation in vivo in the absence of Coro 1A. 
Coro 1A-/- GFP or WT GFP Tcon cells were injected into lethally irradiated B6D2 mice. (A) 
Spleens from WT and Coro 1A-/- recipients were harvested 3 days post transplantation. Donor 
(GFP+) T cells were analyzed by flow cytometry for the loss of proliferation dye and expression 
of CD69, CD25, CD62L, and ICOS. n=4 for Coro 1A-/- and WT recipients. (B) 10 days post 
Supplementary Figure 3.S2
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transplantation, mice were injected with BrdU. Four hours after injection, spleens were harvested 
and analyzed by flow cytometry for BrdU uptake. n=3 for Coro 1A-/- and WT recipients.  
Representative sample shown.  *p<0.05 (C) Freshly isolated T cells from Coro 1A-/- mice were 
placed inside a chemotaxis chamber with indicated amounts of CCL19 or supernatant from bone 
marrow derived B6D2 dendritic cells. 
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Supplementary Figure 3.S3: p38 expression in Coro 1A-/- T-cells. 3 x 106 Coro 1A-/- or WT T 
cells were stimulated for 30 minutes with either 20ng of soluble TNF or 20 µg of anti-CD3 and 
10 µg of anti-CD28 antibodies. Following stimulation the cells were harvested and western blots 
performed as described in Materials and Methods.  
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CHAPTER FOUR 
MUTLIMODALITY TREATMENT TARGETING REGULATORY T CELL NUMBER 
AND FUNCTION DIMINISHES TUMOR GROWTH OF TRIPLE NEGATIVE 
CLAUDIN-LOW BREAST CANCER3 
 
4.1 Introduction 
 Breast cancer is the leading cancer diagnosis and second-leading cause of cancer death 
for women in the United States [1].  Clinically, patient prognosis is determined by stratifying 
patients based on cell-surface expression of Estrogen Receptor (ER), Progesterone Receptor 
(PR), and Human Epidermal Growth Factor Receptor 2 (HER2) [2].  Early diagnosis and 
targeted therapy, both hormonal and immunologic, are critical for the effective treatment of this 
disease.  However, the survival benefit from recent therapeutic advances has been 
disproportionately distributed across the breast cancer subtypes.  Triple negative breast cancers, 
lacking expression of ER, PR, and HER2, continue to carry the worst prognosis, due to higher 
grade at diagnosis, lack of targeted therapy, and an increased propensity for relapse and early 
metastasis [3]. 
 Genetic differences between breast cancers at the transcriptome level have allowed gene 
expression profiling to delineate 6 intrinsic subtypes of breast cancer: Luminal A, Luminal B, 
Normal-like, HER2-Enriched, Basal-like, and Claudin-low [4, 5].  The basal-like and claudin-
low subtypes, which make up the majority of triple negative breast cancers, are separated from 
                                                
3 Taylor NA, Iglesia MD, Vincent BG, Pfefferle AD, Usary J, Carey LA, West ML, Burgents JE, 
McKinnon KM, van Deventer HW, Brickey J, Perou CM, Blazar BR, Serody JS. Unpublished. 
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the other intrinsic subtypes by increased expression of proliferation markers and immune genes 
[6].  Claudin-low tumors are further separated from basal-like tumors by their decreased 
expression of cell-cell adhesion claudin proteins, increased epidermal-to-mesenchymal transition 
markers, and stem cell-like characteristics [4, 7, 8]. 
 Not all cancer growth is dependent on tumor intrinsic genetic factors.  Extrinsic factors 
derived from the tumor microenvironment, including the tumor stroma and the local immune 
response, can both shape and drive tumor growth [9].  Fibroblast deposition of extracellular 
matrix and growth factor production is critical for tumor growth.  Immune cells contribute to 
tumor progression through the production of soluble factors that regulate cell proliferation, 
migration, and angiogenesis [9, 10].  The tumor microenvironment even promotes the activation 
of immunosuppressive cells that prevent the development of an effective anti-tumor immune 
response [11].  Interestingly, the intrinsic subtypes of breast cancer display an inverse correlation 
between survival and immune response [12-14].  The luminal A subtype, which exhibits no 
appreciable immune cell infiltration, carries the best prognosis, while triple negative breast 
cancers, chiefly comprised of the basal-like and claudin-low intrinsic subtypes, exhibit a vast 
immune infiltrate and the worst survival.  
 Our laboratory has previously shown that even with induction of anti-tumor lymphocytes, 
the immunosuppressive tumor microenvironment dominates the immune response and 
diminishes lymphocyte functionality [11].  Immune checkpoint inhibitors, such as anti-CTLA-4, 
anti-PD-1, and anti-PDL-1 have shown no efficacy in their ability to treat breast cancer, which is 
surprising given the lymphoproliferative response seen in some tumors [15, 16].  This finding 
may be the result of two different hypotheses: (1) the types of immune cells that infiltrate breast 
cancer tumors are not amenable to checkpoint inhibition; (2) the types of breast cancer being 
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treated are not the types of breast cancer that are infiltrated with checkpoint inhibition responsive 
lymphocytes.  The latter possibility becomes an increasingly plausible scenario when the 
incidence of intrinsic subtypes is considered.  Luminal A and B tumors account for 
approximately 60% of newly diagnosed breast cancers [2, 17].  However, we have previously 
discussed that these subtypes exhibit no appreciable immune infiltrate.  Thus, the inclusion of 
Luminal A tumors in studies evaluating the efficacy of immunotherapies of breast cancer as a 
single disease is biased towards a null result.  Therefore, it is imperative to test immunotherapy 
treatment efficacy in a subtype specific approach. 
  Genetically engineered mouse models (GEMMs) provide a robust model to study tumor-
specific differences in immune response.  Previous evaluations of clinical approaches to therapy 
using mouse models of breast cancer have delivered disappointing findings that are not 
recapitulated in human studies.  However, these studies relied on xenogeneic transplant models, 
preventing the study of tumor progression in an immunocompetent host.  GEMMs, conversely, 
provide the ability to recreate natural tumor biology in the setting of an immunocompetent host 
and allow us to study the role of the immune response in tumor progression, as well as the effects 
of immunotherapy treatment.  The GEMMs described in this study include tumor models derived 
from the p53-/- BALB/c mouse and the Neu-N mouse [11, 18].  Tumor models from these mice, 
2250, NT2, 2225, and T11, recapitulate, at the genetic level, the human Luminal A, HER2-
Enriched, Basal-like, and Claudin-low subtypes, respectively. 
 In this manuscript, we evaluate the role that the immune response plays in the growth of 
several different intrinsic subtypes of breast cancer.  We find that basal-like and claudin-low 
tumors are heavily infiltrated with immunosuppressive cells and that targeting these immune 
cells offers a new avenue of therapy for these subtypes of breast cancer.   
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4.2 Methods 
Mice and cell lines 
 BALB/cJ and C57Bl/6J (termed B6) females were purchased from The Jackson 
Laboratory (Bar Harbor, ME).  C.Cg-Foxp3tm2(EGFP)Tch/J (termed FoxP3GFP) and C.B6-Tg(Foxp3-
DTR/EGFP)23.2Spar/Mmjax (termed FoxP3DTR) were purchased from The Jackson Laboratory.  
Neu-N mice were purchased from Charles River Laboratory (Wilmington, MA).  Female mice 
(8-14 weeks) were used for all experiments.  Rat neu-expressing NT2 cells and the 2250, 2225, 
and T11 tumor models have been described [11, 18].  2250 cells were prepared by harvesting a 
2250 tumor from a tumor-bearing mouse, manual digestion with razor blades, and chemical 
digestion with Liberase TM (Roche, Basel, Switzerland) and DNase I (Sigma-Aldrich, St. Louis, 
MO).  Digestion was stopped by addition of EDTA.  BALB/c mice were injected with 1 x 106 
2250 cells in Matrigel or 1-5 x 104 T11 cells in PBS.  Neu-N mice were injected with 5 x 104 
NT2 cells in PBS.  Tumors were orthotopically transplanted by intradermal injection into the 
mammary fat pad and measured as previously described [11].  Blood and serum samples were 
harvested by cardiac puncture at time of sacrifice.  All experiments were conducted in 
accordance with protocols approved by the University of North Carolina Institutional Animal 
Care and Use Committee (IACUC). 
 
Human breast tumor microarray data sets 
 All human tumor and normal tissue samples were collected using Institutional Review 
Board (IRB)-approved protocols and were obtained from fresh frozen invasive breast carcinomas 
that were profiled, as described previously, using oligo microarrays (Agilent Technologies, Santa 
Clara, CA, USA) [18, 19].  We used the microarray data set previously published by Prat, et al., 
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as the UNC337 data set (GEO accession number: GSE18229) [4].  All microarray and patient 
clinical data are available in the University of North Carolina Microarray Database [20].  The 
probes for all analyses were filtered by requiring the lowest normalized intensity values in both 
sample and control to be greater than 10.  The normalized log2 ratios (cyanine-5 (Cy5) dye 
intensity for experimental samples/cyanine-3 (Cy3) dye intensity for reference) of probes 
mapping to the same gene (EntrezGene ID as defined by the manufacturer) were averaged to 
generate independent expression estimates. 
 
Mouse breast tumor microarray data sets 
 All mouse samples from UNC were collected from fresh frozen invasive breast 
carcinomas, as described previously, using Agilent mouse oligo microarrays [18].  Data 
normalization and preprocessing were identical to that described for the UNC337 data set.  We 
used 2 samples obtained from the combined data set previously published by Pfefferle, et al. 
(GEO accession numbers: GSE3165, GSE8516, GSE9343, GSE14457, GSE15263, GSE17916, 
GSE27101, and GSE42640) [21].  The remaining 57 samples represent newly obtained tumor 
samples using methods approved by IACUC animal husbandry guidelines.  Total RNA was 
purified from 20 to 30 mg of mouse mammary tumor using the Qiagen (Valencia, CA USA) 
RNeasy Mini Kit following the manufacturer’s protocols.  RNA quantity and quality were 
determined using the Nanodrop spectrophotometer and Agilent Bioanalyzer, respectively.  Total 
RNA was reverse transcribed and labeled with Cy5 dye for experimental samples and Cy3 dye 
for mouse reference samples using the Agilent Low RNA Input Fluorescent Linear 
Amplification Kit [18].  Equal quantities of labeled mouse reference RNA and tumor RNA were 
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co-hybridized overnight to Agilent microarrays, washed, scanned, and signal intensities were 
determined. 
 
Microarray data analysis 
 Hierarchical clustering of the UNC337 data set to group samples by intrinsic subtype was 
performed using the intrinsic gene list as described by Parker, et al. [22].  Centroid linkage 
hierarchical clustering was performed using Cluster v3.0 [23].  Student’s t-tests for gene 
expression data were performed using R [24]. 
 
H&E and Immunofluorescence of patient samples 
 Tumor infiltrating lymphocytes were stained on 85 breast cancer whole tissue sections 
(WTS) obtained from UNC hospitals surgical pathology archives.  Immunohistochemistry (IHC) 
and dual immunofluorescence (IF) on WTS with immune infiltrates were performed in the Bond 
fully-automated slide staining system (Leica Microsystems) using Bond Polymer Refine 
Detection kit (DS9800).  Slides were deparaffinized in Bond dewax solution (AR9222) and 
hydrated in Bond wash solution (AR9590).  Antigen retrieval was done at 100 oC either in Bond-
epitope retrieval solution 1 pH6.0 (AR9661) or in solution 2 pH9.0 (AR9640).  IHC slides were 
visualized with the 3,3’-diaminobenzidine (DAB) and counterstained with hematoxylin using the 
Bond Polymer Refine Detection (DS9800).  Stained slides were dehydrated and coverslipped.  IF 
slides were counterstained with Hoechst 33258 (Invitrogen, Carlsbad, CA) and mounted with 
ProLong Gold antifade reagent (P36934, Life Technologies).  
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Imaging and digital image analysis 
 H&E and IF (CD4, CD8, CD19, and FoxP3) stained slides were digitally imaged at 20X 
magnification using the Aperio ScanScope XT (Aperio Technologies).  The hematoxylin and 
DAB OD parameters were adjusted for both algorithms.  The nuclear segmentation factor and 
the weak positive threshold were tuned for the cytoplasmic v2 and the color deconvolution v9 
algorithms, respectively.  High-resolution acquisition (20X objective) of the stained slides in the 
DAPI, Cy3 and Cy5 channels was performed in the Aperio ScanScope FL (Aperio Technologies, 
Vista, CA).  Cell Nuclei were visualized in DAPI channel (blue); CD8, CD19, and FoxP3 were 
visualized in the Cy3 channel (green); CD4 was visualized in the Cy5 (red) channel.  To 
determine the number of cells co-expressing FoxP3/CD4, slides were analyzed using the 
Definiens Tissue Studio image analysis software (Architect XD v 2.0.4, Tissue Studio v 3.5, 
Munich, Germany). 
 
Antibodies and flow cytometry 
 Human antibodies: Mouse monoclonal antibodies against human CD4 (clone 4B12), 
CD8 (clone 4B11), and CD19 (clone BT51E) were purchased from Leica Microsystems, Inc. 
(Norwell MA).  FoxP3 (clone 236A/E7) was purchased from Abcam (Cambridge, MA).  CD279 
(PD-1, clone J105) was purchased from eBioscience (San Diego, CA).  
 Mouse antibodies: Flow cytometry antibodies against murine CD4 (GK1.5), CD8 (53-
6.7), PD-1 (J43 or RMP1-30), and CXCR4 (2B11) were purchased from eBioscience.  CD45 
(30-F11) and CD19 (1D3) were purchased from BD Horizon and BD Pharmingen, respectively.  
Intracellular antibodies FoxP3 (FJK-16s) and TNF (MP6-XT22) were purchased from 
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eBioscience.  CD4 (RM4-5) was purchased from eBioscience or Invitrogen.  Cell viability was 
determined using Blue Fluorescence Reactive Dye (Life Technologies).  
 Flow cytometry: Cells were surface stained, fixed/permeabilized overnight using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience), and intracellular stained the 
following day according to manufacturer’s instructions.  Data were acquired using the 
MACSQuant (Miltenyi Biotec, Cambride, MA) or BD LSR II (BD Biosciences, San Jose, CA).  
Acquired data were analyzed using FlowJo Flow Cytometry Analysis Software (Tree Star Inc., 
Ashland, OR). 
 
Isolation of murine tumor-infiltrating lymphocytes (TILs) 
 Murine tumors were resected and digested in Liberase TM (Roche), DNase I (Sigma), 
Hyaluronidase (Sigma), and Collagenase XI (Sigma), as previously described [25].  Single cell 
suspensions were enriched for lymphocytes by isolating cells at the interface of a 44% Percoll 
(Sigma) in media and Lympholyte-M (Cedarlane, Burlington, NC) gradient.  Isolated cells were 
stimulated for 4 hours in PMA/ionomycin prior to antibody staining.  
 
In vivo cell inhibition and depletion 
 Monoclonal antibodies used for in vivo antibody inhibition and depletion were purchased 
from BioXCell (West Lebanon, NH).  Mice undergoing immune checkpoint inhibition received 
intraperitoneal (i.p.) injection of 100 µg anti-CTLA-4 (9D9), 200 µg anti-PD-1 (J43), or isotype 
antibody on day -1 post-tumor implantation (PTI) and then every other day [26].  Mice 
undergoing myeloid derived suppressor cell depletion received i.p. injection of  200 µg anti-Gr-1 
(RB6-8C5) or isotype antibody on day  -1, +1 and then every 3 days [11].  Mice receiving 
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lymphoid cell depletion received 500 µg anti-CD4 (GK1.5), 500 µg anti-CD8 (53-6.72), or 
isotype antibody on day -1, +1, and then biweekly [11].   
 Mice undergoing regulatory T cell (Treg) depletion received i.p. injection of 100 mg/kg 
cyclophosphamide on day +2 or +6 PTI [11].  Foxp3DTR mice received i.p. injections of 1 µg 
diphtheria toxin on day -1, +1, +6, and +7 [27].   
 
Treg suppression assay 
 FoxP3+GFP+ cells were sorted using the MoFlo cell sorter (Beckman Coulter, Pasadena, 
CA).  Stimulator cells were isolated from WT B6 splenocytes following CD90 microbead-
depletion (Miltenyi) and irradiation at 2100 cGy.  Responder cells were isolated from WT 
BALB/c mice using the Cedarlane T recovery column kit.  Isolated cells were then B220 and 
CD25 depleted using phycoerythrin (PE) conjugated antibodies and anti-PE magnetic bead 
sorting (Miltenyi).  Responder cells were stained with the Cell Proliferation Dye eFlour 670 
(eBioscience) and plated at varying Treg:Effector cell ratios.  Cells were cocultured for 3 days, 
stained, and FACS analyzed. 
 
Real-time PCR array 
 Whole tumor RNA was isolated using RNEasy kit (Qiagen) and reverse-transcribed.  
Real-time PCR was performed on the ABI 7300 (Applied Biosystems Inc.), using master mix 
from the PAMM-011 RT2 Profiler PCR Array System (Qiagen).  Ct values were determined by 
the ABI software.  Data analysis was performed using the web-based RT2 Profiler PCR Array 
Data Analysis version 3.5 (Qiagen).  
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AMD3100 
 Alzet osmotic pumps, model 2002 (Alza, Palo Alto, CA), were loaded with 10 mg 
AMD3100 (Tocris, Bristol, UK) in PBS or PBS alone [28].  Pumps were subcutaneously 
implanted dorsally on day -2. 
 
Statistical analysis 
 Data are presented as mean ± standard error of the mean (SEM).  Statistical differences 
were determined using Student’s t-test, Mann-Whitney test, or Kruskal-Wallis test, with Dunn’s 
post-test for multiple comparisons, where appropriate.  Survival data are presented using the 
Kaplan-Meier survival analysis.  Survival results were analyzed using the Log-rank test.  
Statistical analyses were conducted using Prism 6 software, unless otherwise noted.  Results 
were considered statistically significant (*) if p ≤ 0.05. 
 
4.3 Results 
Immune gene expression separates intrinsic subtypes of breast cancer. 
 The original gene array used to delineate the intrinsic subtypes of breast cancer analyzed 
expression differences of over 1700 genes [5, 29].  This gene list encompassed endothelial cell 
markers, stromal and fibroblast markers, breast basal epithelial markers, breast luminal epithelial 
markers, adipose-enriched and normal breast markers, and immune cell markers, including T 
cells, B cells, and macrophages.  We sought to determine whether there was an intrinsic 
difference in immune infiltrate and response by evaluating the expression of approximately 100 
immune genes that encompass downstream effector molecules, chemokines and chemokine 
receptors, immune response signal mediators, cell-specific markers, and markers of oxidative 
stress, termed the Intrinsic Immune Genes (IIGs; Supplementary Table 4.1).  The UNC 337 
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patient database underwent unsupervised clustering by the 1900 intrinsic gene list published by 
Prat, et al.  Figure 4.1A demonstrates the relative level of expression of the IIG list by subtype.  
Luminal A and B tumors have low levels of immune gene expression, while the highest levels of 
expression were found in basal-like and claudin-low tumors.   
 The power of the immune response to stratify subtypes is not limited to preclassification 
by the full 1900 intrinsic genes.  Unsupervised clustering of the same UNC 337 database by only 
those genes in the IIG list divides human patients into three clusters: low-expressing luminal 
tumors, moderate expressing normal-like tissue, and high immune gene expressing basal-like and 
claudin-low tumors, which make up the majority of triple negative breast cancers (Figure 4.1B).  
As expected by the heat map, luminal tumors exhibit significantly lower immune gene 
expression than normal-like (p < 0.03), basal-like (p = 0.003), or claudin-low tumors (p < 
0.0001).   
 In order to determine whether these genes were aberrantly expressed by tumor cells or 
were due to differences in immune cell infiltration, patient biopsy samples were studied by 
histology and immunofluorescence (IF).  Figure 4.1C shows H&E examples of the greatest area 
of immune infiltration by a representative luminal A and claudin-low tumor.  IF staining sections 
were then scored for the presence of CD4, CD8, and FoxP3 by whole slide analysis.  
Representative pictures of CD4 (red) and FoxP3 (green) IF staining from the highlighted areas in 
Figure 4.1C demonstrate the differential levels of immune cell infiltration into the tumor (Figure 
4.1D).  Following whole slide analysis of IF samples, claudin-low tumors were found to recruit 
significantly more CD4+ T cells to the tumor site than luminal A tumors (p = 0.002; Figure 
4.1E).  While there were local areas of increased infiltration by specific subtypes in certain 
tumors, such as FoxP3-expressing CD4+ T cells, differences were not statistically significant 
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when the whole tumor section was analyzed (data not shown).  However, this may be due to 
increased heterogeneity of patient samples, as there may have been significant differences in the 
time for tumor growth for different patients in this analysis.  Nonetheless, these data indicate the 
heterogeneity of the immune response in subtype specific breast cancer with luminal tumors 
having little to no immune infiltrate, and basal-like and claudin-low tumors having a significant 
immune cell infiltrate.   
  
Genetic Mouse Models of the Intrinsic Subtypes 
 Given the difficulties with standardizing tumor latency using clinical samples, we sought 
a method to more precisely analyze the early events surrounding the immune response in breast 
cancer.  Previous work has indicated that there are several genetically engineered mouse models 
(GEMMs) that recapitulate tumor growth similar to that found in their clinical counterparts [18, 
21].  Unsupervised clustering of these models on the IIG list recreates the clustering profile seen 
in human samples (Figure 4.1F).  Here we see the same gradation in immune gene expression 
seen in Figure 4.1A, from very little in 2250 tumors (LumA) to very high expression by T11 
tumors (CL).  In order to study the immune infiltrate of the intrinsic subtypes over time, a cell 
line derived from the T11 parental tumor was used to standardize tumor injections and prevent 
contamination by other immune cells.  Supplementary Figure 4.S1 shows that the parental T11 
tumor and tumors derived from injection of the T11 cell line cluster tightly together within the 
claudin-low subtype, demonstrating that T11 cell line tumors can be used to study claudin-low 
tumor progression. 
 
 124 
Claudin-low tumors recruit increased numbers of immune cells, including regulatory T cells, to 
the tumor site. 
 GEMM tumors representing the various subtypes were studied to evaluate the immune 
response as the tumor progresses.  WT BALB/c mice were injected with 1 x 106 2250 cells or 1 x 
104 T11 cells.  Neu-N mice were injected with 5 x 104 NT2 cells.  Tumors were harvested at 
approximately 20 mm2 (Figure 4.2A – 4.2D) and 100 mm2 (Figure 4.2E – 4.2H) and FACS 
analyzed to determine the type, percentage, and number of tumor-infiltrating lymphocytes (TILs) 
over time.  Representative FACS analysis workflow is shown in Supplementary Figure 4.S2.  
The number of cells of all cell types recruited to the tumor site is significantly increased in 
claudin-low tumors (Figure 4.2).  Surprisingly, FoxP3+ regulatory T cells can account for over 
67% of all CD4+ T cells in T11 tumors.   
 To ensure that these FoxP3-expressing cells were functional, Treg suppression assays 
were performed (Figure 4.3A and 4.3B).  FoxP3GFP mice were injected with 1 x 104 T11 cells.  
When tumors reached 20 mm2 (Figure 4.3A) or 100 mm2 (Figure 4.3B), tumor and spleen were 
harvested for sorting.  Treg frequency was too low in a digested tumor without lymphocyte 
enrichment, preventing the use of Treg TILs.  Therefore, GFP+ (FoxP3+) splenocytes were used.  
As seen in Figure 4.3, FoxP3+ cells from tumor bearing mice were able to suppress T cell 
proliferation in a mixed lymphocyte reaction. 
 
Regulatory T cells suppress anti-tumor immune response 
 The most notable finding from the immune surveillance data presented above was the 
variability in percentage of FoxP3+ cells infiltrating T11 tumors (Figure 4.2D and 4.2H).  
Further, there was an inverse relationship between percentage of infiltrating Treg 
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percentage of infiltrating CD8+ T cells and CD19+ B cells (Figure 4.4A and 4.4B).  Indeed, the 
percentage of Treg TILs inversely correlated with percentage of CD8+ TIL and CD19+ TILs (R2 
values: 0.71 and 0.93, respectively).  This finding led us to hypothesize that approaches that 
target Treg cells may be able to lift the immune suppression inhibiting the proliferation of CD8+ T 
cells and enhance the anti-tumor immune response.   
 To deplete Treg cells, we made use of mice in which the diphtheria toxin receptor had 
been knocked into the FoxP3 locus.  Administration of diphtheria toxin to these mice will result 
in the loss of cells that express FoxP3.  FoxP3DTR (DEREG) mice were injected with 1 x 104 T11 
cells and treated with diphtheria toxin (DT) on days -1, 0, +1, and +6 to specifically deplete Treg 
cells.  DT treated mice exhibited a modest delay in tumor growth and increase in survival (Figure 
4.4C and 4.4D), but all mice eventually succumbed to either autoimmunity or tumor.   
 Alternatively, in an attempt to use non-genetic approaches to treatment, tumor bearing 
WT mice received a single treatment of low-dose (100 mg/kg) cyclophosphamide (Cy) 2-6 days 
post-tumor implantation to selectively deplete Treg cells.  As with DT treatment, a single 
injection of low-dose Cy delayed tumor growth (Figure 4.4C and 4.4D), but, again, all mice 
eventually succumbed to tumor.  While Treg cell numbers were decreased compared to untreated 
T11 tumors, they have begun to rebound by the time the tumor has reached 20 mm2 (Figure 
4.4E). 
 Although Treg depletion delays growth, T11 tumors invariably progress.  Therefore, we 
sought to determine other targetable mediators of Treg function that could be treated over longer 
periods of time.  As expected, tumor infiltrating FoxP3+ Treg cells expressed higher levels of both 
PD-1 and CTLA-4 than CD8+ T cells or non-Treg CD4+ T cells (Supplementary Figure 4.S3A – 
4.S3D).  T11 tumor-bearing mice were treated with 100 µg anti-CTLA-4, 200 µg anti-PD-1, or 
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isotype antibody beginning on day -1 and continuing every other day.  Treatment with ant-PD-1 
or anti-CTLA-4 alone had no effect on tumor growth (data not shown).  Combination therapy 
with both PD-1 and CTLA-4 slightly decreased tumor growth, but had no significant effect on 
survival (Supplementary Figure 4.3SE and 4.S3F).   
 
Multimodality therapy delays growth of claudin-low tumors 
 Although Cy alone and PD-1/CTLA-4 inhibition alone were insufficient to delay tumor 
growth, combination therapy using Cy, anti-PD-1, and anti-CTLA-4 mAb to decrease Treg cell 
number and inhibit the function of rebounding Treg cells increased survival (Figure 4.5A).  
Interestingly, a moderate effect was seen with isotype antibody, but not the magnitude seen with 
anti-PD-1 and anti-CTLA-4 treatment (data not shown).  Consistent with the variability of Treg 
and CD8+ T cell infiltration in untreated tumors (Figure 4.4A), combination therapy resulted in 
variable tumor growth curves (Figure 4.5B).  This variability ranged from non-responding mice 
resembling those treated with Cy alone, to 12% of mice not developing tumors.  Interestingly, 
mice that responded to combination therapy demonstrated decreased percentages of CD4+ and 
CD8+ T cells in the tumor (Supplementary Figure 4.S4A and 4.S4B).  However, in the tumor 
draining lymph node (TDLN), there was increase in CD8+TNF+ cells and a compensatory 
increase in CD4+FoxP3+ Treg cells (Supplementary Figure 4.S4C and 4.S4D).  Although one of 
the main side effects seen in human trials evaluating anti-PD-1 and anti-CTLA-4 therapy was 
elevated liver enzymes, no differences in liver function tests were seen in our study 
(Supplementary Figure 4.S4E – 4.S4G). 
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CXCL12 may recruit Treg cells to claudin-low tumors via CXCR4 
 In an effort to determine what mediators were responsible for recruiting Treg cells to the 
tumor site, an RT2 Profiler PCR Array was used to compare gene expression differences between 
NT2 and T11 tumors (Figure 4.6A).  Surprisingly, T11 tumors expressed significantly higher 
levels of multiple chemokines, with CXCL12 being 22-fold higher expressed (95% CI: 17.1 – 
28.3; p < 0.001).  ELISA of tumor homogenate for CXCL12 confirmed the array, with T11 
tumors expressing higher levels of CXCL12 protein than Neu-overexpressing tumors (Figure 
4.6B).  Elevated levels of CXCL12 protein were even seen in the serum of tumor bearing mice, 
although the difference did not reach statistical significance (Figure 4.6C).  Further support for 
the role of CXCL12 in Treg recruitment to claudin-low tumors came from the finding that FoxP3+ 
Treg cells that infiltrate T11 tumors demonstrated higher expression levels of CXCR4, the 
classical receptor for CXCL12, than either non-Treg CD4+ T cells (p = 0.03) or CD8+ T cells (p = 
0.003; Figure 4.6D and 4.6E). 
 In order to disrupt this pathway, mice were treated with the CXCR4 inhibitor AMD3100.  
Due to the short half-life of AMD3100, Alzet osmotic pumps were loaded with 10 mg 
AMD3100 or PBS control, primed, and dorsally implanted subcutaneously on day -2.  Mice were 
then challenged with 1 x 104 T11 cells and tumors were harvested at approximately 20 mm2. 
Although control and treated mice exhibited similar percentages of Treg cells recruited to the 
tumor, there was a decrease in Treg cell number in AMD3100 treated mice (Figure 4.7A), which 
was greater when comparing the number of FoxP3+PD-1+ Treg (p = 0.07) cells in the tumor 
(Figure 4.7B).  These data suggest that one mechanism by which Treg cells are recruited to the 
site of T11 tumor growth is via recruitment of CXCR4-expressing Treg cells by T11-expressed 
CXCL12.   
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4.4 Discussion 
 Triple negative breast cancer has the worst prognosis of the histologic subtypes due to 
higher grade at diagnosis and short time to metastasis.  The counter-intuitive observation that 
these tumors also exhibit high levels of immune cell infiltration suggests that these infiltrating 
cells may have a deleterious impact on patient outcome.  Our study supports this conclusion, as 
basal-like and claudin-low tumors, which make up the majority of triple negative breast cancers, 
exhibit the highest levels of immune gene expression.  Indeed, clustering by the intrinsic immune 
genes alone is sufficient to separate triple negative basal-like and claudin-low tumors from 
luminal tumors and normal tissue.  Further, this finding is not due to aberrant gene expression by 
tumor cells, but by increased immune cell infiltration into the tumor, especially CD4+ T cells.  
 The use of mouse models that truly mimic tumor biology seen in human patients is 
critical to finding pathways important for tumor pathogenesis, as well as potential treatments.  
The GEMMs utilized by our laboratory, 2250, NT2, and T11 are derived from, and studied in, 
immunocompetent mice that recapitulate tumor biology at the genetic and whole tumor level.  As 
expected by the human patient samples, murine tumors exhibit significant differences in immune 
cell infiltration based on intrinsic subtype.  Indeed, one possible cause of the poor prognosis 
associated with claudin-low tumors is the large proportion of FoxP3+ Treg cells that infiltrate 
tumors.  Ranging almost as high as three-quarters of all CD4+ cells in the tumor, these cells are 
both functional and continue to infiltrate as the tumor grows.  What was most surprising is that 
Treg cells can dominate the immune response, preventing the proliferation and infiltration of 
CD8+ T cells.   
 Treatments that eradicate Treg cells from the tumor are critical in order to permit a viable 
anti-tumor response to occur.  To demonstrate this, we found that the depletion of Treg cells using 
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the FoxP3DTR transgenic mouse and diphtheria toxin treatment delayed tumor growth.  More 
applicable to human patients, low-dose cyclophosphamide, shown to preferentially deplete Treg 
cells when administered early following tumor implantation, reproduced the growth curve seen 
with the FoxP3DTR model, and reduced the total number of Treg cells.  This number even remains 
low by the time the tumor has reached 20 mm2, despite the use of only a single Cy dose.  The 
therapeutic effect seen with only Treg depletion suggests that there is an ongoing anti-tumor 
response that is incapable of overcoming the immunosuppressive tumor microenvironment.  
Even in the absence of adoptive cell transfer, this response is capable of delaying tumor growth 
when the immunosuppression is relieved.  Although we cannot rule out a possible anti-tumor 
chemotherapeutic effect by Cy, it is not believed to be the mechanism of action seen here as 
multiple other cytotoxic drugs have no activity against T11 tumors (Perou and Serody, 
unpublished).  Also, any additional chemotherapeutic effect of the treatment would be beneficial 
to the patient.  Unfortunately, the use of Cy to deplete Treg cells is limited to the narrow window 
following tumor implantation, when Treg cells are activated to self-antigen, but before CD8+ 
effector T cells are activated to tumor-associated antigen.  Later administration of Cy leads to 
loss of the anti-tumor effector immune response and enhances tumor growth.   
 Immune checkpoint inhibitors PD-1 and CTLA-4 provide promising targets to further 
suppress Treg cell function in vivo.  Unfortunately, these targets have shown no efficacy in the 
limited number of human breast cancer patients in which they have been tested [15, 16].  This is 
not a surprising result, however, since luminal tumors account for up to 60% of newly diagnosed 
tumors, but exhibit almost no immune cell infiltration.  Therefore, the use of these inhibitors in 
subtype appropriate trials may elucidate an effect that has so far been masked.  Indeed, 
combination therapy with Cy and immune checkpoint inhibition significantly delayed tumor 
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growth beyond that seen with Cy alone.  Further, a small subset of mice failed to develop tumors.  
While the variability in treatment response may seem confusing, it reinforces the stochastic 
nature of the immune response seen in untreated mice.  As the response develops as either Treg 
dominated or effector cell dominated (Figure 4.4), combination therapy, as described here, only 
moves mice down the curve shown in Figure 4.4.  Unfortunately, in the absence of adoptive cell 
therapy, it is not able to move mice along the curve to a more CD8-dominated response.  
Therefore, inhibition of Treg cells in mice that never develop a CD8+ T cell response succumb to 
tumor early.  Meanwhile, mice who are capable of mounting a CD8 response, which is only 
suppressed by Treg cells, can go on to clear tumor following Treg depletion and inhibition.  Also 
promising for the use of these inhibitors in human patients is the finding that mice receiving 
treatment did not exhibit the elevation of liver enzymes that can be seen in humans.  
 Finally, we sought to determine mechanisms that account for the preferential recruitment 
of Treg cells to claudin-low tumors.  CXCL12, a chemokine critical for homing of hematopoietic 
stem cells to injured tissue, is 22-fold higher expressed in T11 tumors than Neu tumors.  Further, 
Treg cells that infiltrate claudin-low tumors express high levels of CXCR4, the classical receptor 
for CXCL12.  Therefore, inhibition of this axis may provide further benefit by preventing the 
recruitment of Treg cells during tumor development.  Inhibition of CXCR4 with AMD3100 
illustrates a partial role for this axis in Treg recruitment.  AMD3100-treated mice demonstrated a 
trend to decreased Treg cell number in the tumor compared to controls.  This trend was even 
stronger for PD-1+ Treg cells in the tumor.  
 In summary, we have found that the two major subtypes of triple negative breast cancer, 
basal-like and claudin-low, are highly enriched with immune cells.  Enhancing the immune 
response to these tumors was an effective therapy in our GEMM models, but required targeting 
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both the function and number of Treg cells.  We found that the generation of CXCL12 by the 
tumor cells played a role in the recruitment of Treg cells to the tumor site.  These studies suggest 
that future clinical trials for patients with triple negative breast cancer should target the 
immunosuppressive environment generated by the tumor, perhaps in combination with active 
vaccine therapy.   
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Figure 4.1: Human tumors exhibit differential immune gene expression. (A) Expression of 
intrinsic immune genes by intrinsic subtypes from UNC337. (B) Unsupervised clustering of 
UNC337 by intrinsic immune gene list and overall expression by each subtype. (C) 
Representative H&E staining of human tumor (5X magnification). (D) Representative 
immunofluorescence staining of human tumors for CD4 (red) and FoxP3 (green) (20X 
magnification). (E) Whole slide scoring of CD4+ infiltrate for each subtype. (F) Unsupervised 
clustering by the intrinsic immune genes of GEMMs. Statistical significance determined by 
Kruskal-Wallis test, with Dunn’s post-test for multiple comparisons. * denotes p < 0.05. ** 
denotes p < 0.01. *** denotes p < 0.001. **** denotes p < 0.0001. 
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Figure 4.2: T11 (Claudin-low) tumors recruit elevated numbers of immune cells to the 
tumor site. WT mice were injected with 1 x 106 2250 tumor cells or 1 x 104 T11 cells.  Neu-N 
mice were injected with 5 x 104 NT2 cells.  Tumors were harvested at 20 mm2 (A-D) or 100 mm2 
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(E-F), digested, enriched for lymphocytes, and FACS analyzed. (A) CD4+ TILs at 20 mm2. (B) 
CD8+ TILs at 20 mm2. (C) CD19+ TILs at 20 mm2. (D) CD4+FoxP3+ TILs at 20 mm2. (E) CD4+ 
TILs at 100 mm2. (F) CD8+ TILs at 100 mm2. (G) CD19+ TILs at 100 mm2. (H) CD4+FoxP3+ 
TILs at 100 mm2.  Statistical significance determined by Kruskal-Wallis test with Dunn’s post-
test for multiple comparisons. * denotes p < 0.05. ** denotes p < 0.01. *** denotes p < 0.001. 
**** denotes p < 0.0001. 
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Figure 4.3: FoxP3+ cells from T11 tumor-bearing mice are functionally suppressive. 
FoxP3GFP mice were injected with 5 x 104 T11 cells. FoxP3+GFP+ splenocytes were sorted from 
tumor-bearing mice at (A) 20 mm2 or (B) 100 mm2, and plated with irradiated allogeneic 
stimulator cells and different ratios of WT effector cells for 3 days.  Effector cells were then 
FACS analyzed for dilution of proliferation dye. n = 3 mice at each tumor size. 
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Figure 4.4: Treg depletion delays tumor growth in the absence of adoptive transfer. The 
immune response that develops against T11 tumors is either Treg dominated or CD8 (A) or CD19 
(B) dominated.  WT untreated, Cy treated, and FoxP3DTR mice were injected with 1 x 104 T11 
cells (n = 5 per group). Cy treated mice received 100 mg/kg Cy on day +2. DTR mice received 1 
µg DT on days -1, 0, +6, and +7. (C) Growth curves. (D) Survival.  There was a significant 
difference in survival between both Treg depleted groups compared with the untreated control 
group (p < 0.05; log-rank test), but not between treated groups.  Treg cells numbers following a 
single dose of Cy are reduced compared to untreated T11 tumors.  Statistical significance 
determined by Mann-Whitney test.  *** denotes p < 0.001.  **** denotes p < 0.0001.  
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Figure 4.5: Multimodality therapy combining Cy with anti-PD-1 and anti-CTLA-4 immune 
checkpoint inhibition significantly delays tumor growth. WT mice were injected with 1 x 104 
T11 cells.  Cy mice received 100 mg/kg on day 2 PTI.  Cy + PD-1 + CTLA-4 mice received 100 
mg/kg Cy on day 2 PTI, and anti-PD-1 and anti-CTLA-4 antibody beginning on day -1, and then 
every other day for the duration of the experiment. (A) Mice treated with low-dose Cy and anti-
PD-1 and anti-CTLA-4 (n = 25) have a significant survival benefit compared to untreated (n=5) 
or Cy treated (n = 5) controls (Cy vs Cy + CLTLA4 + PD-1: p = 0.001; log-rank test). (B) 
Individual replicates of tumor bearing mice show the variability in treatment response. 
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Figure 4.6: T11 tumors express high levels of CXCL12. (A) Whole tumor RNA was isolated 
and analyzed using the PAMM-011 RT2 Profiler PCR Array. Gene expression is presented 
relative to NT2 tumor controls. (B) Tumors were harvested on day 21 PTI, homogenized, and 
analyzed by CXCL12 ELISA (n = 3 per group). (C) Serum was harvested on day 21 PTI and 
analyzed by CXCL12 ELISA (n = 3 per group). (D) Representative overlay of CXCR4 
expression by CD4+FoxP3+ Treg cells (Treg CD4), CD4+FoxP3- T cells (Non-Treg CD4), and CD8+ 
T cells. (E) Mean fluorescence index (MFI) values from untreated T11 TILs at 20 mm2. 
Statistical significance was determined by student’s t-test (B and C) or Mann-Whitney test (E). * 
denotes p < 0.05. ** denotes p < 0.01. 
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Figure 4.7 
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Figure 4.7: CXCL12-CXCR4 pathway is important for Treg infiltration into claudin-low 
tumors. (A and B) WT mice were implanted on day -2 with osmotic pumps loaded with PBS or 
10 mg AMD3100 in PBS (n = 7 per group) and challenged with 1 x 104 T11 cells. Tumors were 
harvested on day 12 PTI and FACS analyzed. (A) Percentage and number of CD4+FoxP3+ TILs.  
(B) Percentage and number of CD4+FoxP3+PD-1+ TILs. (C and D) T11 cell line was transfected 
with lentiviral-expressing CXCL12-targeted shRNA. (C) CXCL12 knockdown was screened 
using real-time PCR and expression levels calculated were calculated using the ΔΔCt method, 
relative to 18S. Samples were normalized to WT control. Scramble 1 and Scramble 2 are non-
targeted shRNA controls, and three knockdown (KD) lines were chosen. (D) CXCL12 
knockdown was confirmed using CXCL12 ELISA. (E and F) WT mice were injected with 1 x 
104 cells of WT, scramble, or KD lines (n = 5 per group). Tumors were harvested on day 13 PTI 
and FACS analyzed. (E) Percentage and number of CD4+FoxP3+ TILs. (F) Percentage and 
number of CD4+FoxP3+PD-1+ TILs. Statistical significance was determined by Mann-Whitney 
test. 
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Supplementary Table 4.1: Intrinsic Immune Genes 
	   	   	   	   	   	   	  Human	  
	  
Mouse	  
	  	  
	  
	  	   	  	   	  	  
	  
	  	  
BCL10	   GCLC	   PARK7	   	  	   BCL10	   EPHX1	   NLRP3	  
BCL2	   GPX1	   PIK3CA	   	  	   BCL2	   FAS	   NOD1	  
BCL2A1	   GSTP1	   POR	   	  	   BCL2a1a	   FOS	   NOS3	  
BCL6	   GZMB	   REL	   	  	   BCL2a1b	   GATA3	   NPM1	  
BIK	   HMOX1	   RELB	   	  	   BCL2a1d	   GCLC	   NQO1	  
BIRC2	   IKBKE	   RIPK1	   	  	   BCL6	   GPX1	   PARK7	  
CAT	   IL15	   RIPK2	   	  	   BIK	   GSTP1	   PIK3CA	  
CCL13	   IL16	   RNF31	   	  	   BIRC2	   GZMB	   POR	  
CCL17	   IL18	   SOCS3	   	  	   CAT	   HMOX1	   REL	  
CCL18	   IL1B	   SOD1	   	  	   CCL21	   IKBKE	   RELB	  
CCL19	   IL1R1	   STAT1	   	  	   CCL17	   IL15	   RIPK1	  
CCL2	   IL2RA	   STAT4	   	  	   CCL19	   IL16	   RIPK2	  
CCL21	   IL6	   STAT6	   	  	   CCL2	   IL18	   RNF31	  
CCL22	   IRAK1	   TLR2	   	  	   CCL21a	   IL1B	   SOCS3	  
CCL24	   IRF1	   TNF	   	  	   CCL22	   IL1R1	   SOD1	  
CCL26	   IRF3	   TNFAIP3	   	  	   CCL24	   IL2RA	   STAT1	  
CCL27	   IRF4	   TNFRSF18	   	  	   CCL26	   IL6	   STAT4	  
CCL5	   IRF6	   TNFRSF1A	   	  	   CCL27a	   IRAK1	   STAT6	  
CCR2	   IRF8	   TNFRSF1B	   	  	   CCL3	   IRF1	   TLR2	  
CCR5	   LTBR	   TNFSF4	   	  	   CCL5	   IRF3	   TNF	  
CD40	   MAP2K1	   	  	   	  	   CCR2	   IRF4	   TNFAIP3	  
CDKN1A	   MAP2K2	   	  	   	  	   CCR5	   IRF6	   TNFRSF18	  
CDKN1B	   MAP2K4	   	  	   	  	   CD40	   IRF8	   TNFRSF1A	  
CEBPB	   MAP3K14	   	  	   	  	   CDKN1A	   JUN	   TNFRSF1B	  
CHUK	   MAPK1	   	  	   	  	   CDKN1B	   LTBR	   TNFSF4	  
CXCL1	   MAPK13	   	  	   	  	   CEBPB	   MAP2K1	   	  	  
CXCL12	   MMP1	   	  	   	  	   CHUK	   MAP2K2	   	  	  
CXCL13	   MMP10	   	  	   	  	   CXCL1	   MAP2K4	   	  	  
CXCL16	   MMP2	   	  	   	  	   CXCL12	   MAP3K14	   	  	  
CXCL2	   MMP7	   	  	   	  	   CXCL13	   MAPK1	   	  	  
CXCL5	   MYC	   	  	   	  	   CXCL16	   MAPK13	   	  	  
CXCL9	   NCF1	   	  	   	  	   CXCL2	   MMP10	   	  	  
CXCR3	   NFE2L2	   	  	   	  	   CXCL5	   MMP1a	   	  	  
CYBB	   NFKB1	   	  	   	  	   CXCL9	   MMP2	   	  	  
CYP2A13	   NFKB2	   	  	   	  	   CXCR3	   MMP7	   	  	  
DDX58	   NFKBIA	   	  	   	  	   CYBB	   MYC	   	  	  
ELK1	   NLRP3	   	  	   	  	   CYP2a12/CYP2a22	   NCF1	   	  	  
EPHX1	   NOD1	   	  	   	  	   CYP2a4	   NFE2l2	   	  	  
FAS	   NOS3	   	  	   	  	   CYP2a5/CYP2a21-­‐ps	   NFKB1	   	  	  
FOS	   NPM1	   	  	   	  	   DDX58	   NFKB2	   	  	  
GATA3	   NQO1	   	  	   	  	   ELK1	   NFKBIA	   	  	  
 144 
	   	   	   	   	   	   	  
Supplementary Figure 4.S1: Tumors derived from T11 cell line result in true claudin-low 
tumors. Three T11 cell line-derived tumors were normalized to a 385 microarray dataset 
consisting of tumors from 27 murine models of breast carcinoma and normal mammary tissue 
[21]. A supervised cluster using murine intrinsic genes was performed, with the sample 
dendrogram displayed. The eight murine classes identified as human subtype counterparts are 
highlighted. The cluster locations of the T11 parental tumor and the three T11 cell line derived 
tumors, which had a dendrogram correlation of 0.84, are displayed below the dendrogram as 
black lines. 
 
  
Erbb2-likeEx NeuEx Normal-likeEx p53null-BasalEx Class14Ex
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Supplementary Figure 4.S2: Representative FACS analysis diagram. Shown is a 
representative gating schema for the FACS analysis of tumor-infiltrating lymphocytes from an 
untreated 20 mm2 T11 tumor. 
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Supplementary Figure 4.S3: PD-1 and CTLA-4 inhibition does not increase survival in T11 
tumor bearing mice. (A and B) Representative FACS overlay (A) and total MFI values (B) of 
PD-1 expression by T11 TILs at 20 mm2. (C and D) Representative FACS overlay (C) and total 
MFI values (D) of CTLA-4 expression by T11 TILs at 20 mm2. (E) Growth curves of T11 tumor 
bearing mice receiving anti-PD-1 and anti-CTLA-4. (F) Survival analysis of data presented in 
(D). Statistical significance was determined by Mann-Whitney test. * denotes p < 0.05.  
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Supplementary Figure 4.S4: Anti-tumor response following combination therapy. WT mice 
were injected with 1 x 104 T11 cells and treated with 100 mg/kg Cy on day +2, and anti-PD-1 
and anti-CTLA-4 antibody on day -1, and then every other day. Mice were sacrificed on day 33 
PTI and classified as Non-Responder (tumor size: 199 ± 14.75 mm2) or Responder (tumor size: 
49.25 ± 11.54 mm2). (A) CD8+ TILs. (B) CD4+ TILs. (C) Tregs in the TDLN. (E) CD8+TNF+ 
cells in the TDLN. (E-F) AST (E), ALT (F), and Total Bilirubin (G) of treated mice.  Statistical 
significance was determined by Mann-Whitney test. * denotes p < 0.05.  
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CHAPTER FIVE 
DISCUSSION 
 
 The proper balance of activating and suppressive signals ensures that the immune system 
maintains homeostasis.  Disease states may arise whenever either side of the scale becomes 
unbalanced, promoting a pro-inflammatory autoimmune state or immunosuppressive 
environment prone to infectious complications.  Immunotherapy has the power to fine-tune this 
balance, in order to promote suppression where there is too much activation, and activation 
where there is too much suppression.  This thesis evaluated the power of immunotherapy by 
studying two dichotomous disease processes: GvHD and tumor immune evasion.  The 
experiments described in this work illuminate the importance of two themes in our ability to 
augment the immune response: (1) location of cell involved in the immune response (2) type of 
the cell involved in the immune response.  Further, findings that result from the study of one 
disease provide us with insights to the treatment of the other.   
 
5.1 Cell location 
 The use of Treg infusion to prevent GvHD following HSCT quickly gained momentum, 
with multiple groups in the United States attempting this approach [1, 2].  In the work presented 
here, we delved deeper into the use of Treg infusion to decrease GvHD, using MPLSM to study 
the in vivo kinetics of Tcon activation and how the inclusion of Treg cells mediate the disruption of 
Tcon activation following allogeneic HSCT.  This study identified three important mechanisms of 
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Treg-induced suppression: (1) physical displacement of Tcon cells from DCs; (2) Treg production 
of IL-10 and down-regulation of CD86 and CD54 on DCs; and (3) the induction of DC death. 
 
Multiphoton Scanning Laser Microscopy 
 MPSLM highlights the importance of cell location in our ability to augment the immune 
response.  Static microscopy images acquired from H&E or immunohistochemistry give us the 
ability to identify cell subsets, but they are only glimpses in time.  It was only through the use of 
MPSLM and its ability to digitally reconstruct and stitch images together that we see how 
important a continuous variable like cell movement is.  For instance, IHC identification of a 
Treg:DC contact is not critical in-and-of itself.  However, visualizing that this contact is necessary 
for preventing Tcon activation and inducing DC death allows us to develop therapies that target 
this interaction.  One possible way to exploit this finding is to include Semaphorin-3A (Sema-
3A) over-expressing DCs and Treg cells as part of the stem cell infusion.  Sema-3A on DCs binds 
Neuropilin 1 (NRP1) on Treg cells to stabilize Treg:DC interactions [3].  In addition, Sema-3A 
binding of NRP1 on naïve T cells prevented their proliferation in the presence of anti-CD3/CD28 
stimulation. 
 The use of MPLSM provides mechanistic insight as to how Treg cells prevent allogeneic 
reactions.  The ability of MPSLM to allow direct observation of cell-cell interactions in vivo is 
unparalleled by other current technologies, allowing researchers to see deeper into tissues than 
ever before.  However, MPSLM is not without its own disadvantages, including the time needed 
for image capture, low resolution of captured images due to the use of near-infrared light, and 
reduced number of fluorescent markers that can be used to visualize samples.   
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 All three of these drawbacks prevent us from being able to determine what is occurring at 
the immunologic synapse in real time as a result of Treg infusion.  Fast fluorescent reporter assays 
to visualize changes in ion flux and signaling pathways are unsuitable to the method described 
here.  The increased time needed for image exposure as the slide is scanned would mask 
transient differences in fluorescent signal.  In addition, the use of near-infrared light results in 
low-resolution images and prevents the use of multiple fluorophores within the same sample.  
Therefore, we cannot obtain high-resolution images of samples labeled with multiple colors, 
which would be needed to study differences in receptor localization at the IS.  These limitations 
also prevent us from directly visualizing FasL and perforin-mediated induction of DC death.  
Although FACS analysis allowed us to determine levels of 7AAD expression by DCs and FasL 
and perforin expression by Treg cells, the cell-cell contact signals required for DC apoptosis 
induction could not be elucidated.  Combining fast fluorescent reporter assays with “large-area” 
non-scanning microscopy or “multi-focal” multiphoton scanning microscopy would allow the 
rapid image acquisition necessary for visualizing transient differences in TCR and co-stimulatory 
signals required for Tcon activation [4-6]. 
 
 Cell Motility 
 As described in Chapter 2, the ability of naïve Tcon cells to migrate through SLT in search 
of APCs is critical for Tcon activation and generation of the allogeneic response.  Following their 
activation, the T cells must then migrate out of SLT to target organs.  The ameboid movement 
necessary for T cell movement is dependent on actin protrusion of the leading edge of the cell 
membrane [7].  This process is regulated by recycling of G-actin and F-actin subunits to allow 
formation and degradation of actin polymers [8].  Therefore, in Chapter 3, we explored 
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cytoskeletal rearrangements as a second, independent target to inhibit Tcon-mediated 
pathogenesis.  Coronin 1A, an actin-associated protein, was shown to be important for 
cytoskeletal rearrangements and cell motility [9, 10].  The expression restriction of Coronin 1A 
to hematopoietically-derived tissues makes it an attractive target to study in GvHD. 
 The impaired migratory ability of Coro 1A-/- T cells was correlated with decreased 
expression of CCR7 and S1Pr1.  An initial therapeutic target, therefore, would be small molecule 
or antibody-mediated inhibition of these receptors.  CCR7 and S1Pr1 expression were also 
correlated with defects in the NF-κB pathway, namely, decreased phosphorylation of the p65 
subunit.  Previous studies have shown that both p65 and Coronin 1A directly interact with actin 
filaments [10, 11].  However, in these experiments, pharmacologic disruption of the actin 
filament resulted in increased p65 translocation and upregulated NF-κB signaling [12, 13].   
 One possible mechanism for this discrepancy is that pharmacologic disruption of actin 
filaments resulted in activation of the inhibitor of NF-κB kinase (IKK), which deactivates the 
inhibitor of NF-κB (IκB) and leads to p65 activation [14].  It is not known what led to activation 
of IKK, but experiments in Drosophila demonstrate that IKK is localized with actin filaments at 
the leading edge of ruffled membranes [15].  Therefore, disruption of actin filaments releases 
sequestration of IKK, degradation of IκB, and p65 activation.  Unfortunately, IKK localization is 
unknown in Coronin 1A-deficient cells, where there is a decreased ability to form actin 
filaments.  It is possible that improper IKK localization in the absence of Coronin 1A leads to 
IKK degradation and decreased p65 activation.  However, actin filaments would be intact in 
human patients, and post-transplant disruption of intact actin cytoskeleton filaments may lead to 
IKK activation, a paradoxical increase in NF-κB signaling, and worsening of disease.  Instead, 
inhibition of down-stream NF-κB signaling pathways should be targeted.  Inhibitors of NF-κB 
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function are already in early phase clinical trials for the direct treatment of cancers, and their use 
to attenuate GvHD is currently being evaluated in mice [16, 17].  Given the cytoskeletal 
rearrangements that occur following TCR activation and subsequent signaling by the NF-κB 
pathway, future studies should seek to determine the direct interaction between Coronin 1A and 
IKK.  This study should also include other actin-associated proteins, like Arp2/3, and other 
components of the NF-κB pathway that are sequestered by the actin cytoskeleton. 
 Another possible mechanism for this discrepancy is the co-interaction of Coronin 1A and 
Rho GTPase Rac1with F-actin at the leading edge of cells [10, 12, 18].  Coronin 1A and Rac1 
form a feedback loop that promotes Rac1 activation [19].  Rac1, in turn, controls p65 
translocation following IL-1-dependent activation, in an IκB-independent manner [20].  
Therefore, decreased Rac1 activation in the absence of Coronin 1A may result in decreased p65 
signaling. 
 
Cell chemotaxis 
 In Chapter 4, we showed that claudin-low tumors express high levels of the chemokine 
CXCL12.  This chemokine is important for homing of stem cells to injured tissue, but has also 
been implicated in multiple models of tumor metastasis [21-25].  Tumor-infiltrating Treg cells 
also express high levels of CXCR4, the classical receptor for CXCL12.  We believe this axis is 
important for the initial and ongoing recruitment of Treg cells that occurs during tumor 
development and progression.  Our data show a partial role for this axis, as inhibition of the 
CXCR4 receptor partially reduced Treg cell infiltration into claudin-low tumors.  In order to 
confirm the role of CXCL12 in Treg recruitment, we have also created T11 cell lines expressing 
CXCL12-specific lentiviral shRNA.  Studying the levels of Treg TILs in CXCL12-knockdown 
 156 
tumors will solidify the importance of this axis in the pathogenesis of claudin-low breast cancer.  
A novel CXCL12 inhibitor, NOX-A12, has already reached Phase II clinical trials for the 
treatment of chronic lymphocytic leukemia (CLL) [26].   
 This axis is not limited to Treg recruitment, either, as the CXCL12-CXCR4 pathway is 
implicated in the spontaneous metastasis of multiple tumor models [21-25].  As CXCL12 
production by bone marrow is important for stem cell homing, tumors that express CXCR4, 
including breast cancer, are able to traffic along this axis.  As expected, CXCL12 inhibition by 
NOX-A12 led to decreased CLL chemotaxis and increased sensitivity to chemotherapeutics.  
These are important findings, as basal-like and claudin-low tumors demonstrate the highest 
capacity for early metastasis, accounting for the poorer survival compared to other intrinsic 
subtypes.  The effect of CXCL12 inhibition on metastatic potential of claudin-low tumors can be 
studied through several models, including the physiologically relevant endogenous metastasis 
model employed by our laboratory. 
 
5.2 Cell type 
Regulatory T Cells 
 Throughout this thesis, the importance of Treg cells in immunotherapy is a recurrent 
theme.  It is one of the best examples of how the immune system can be a two-edged sword, and 
how targeted immunotherapy can lead to disease treatment.  The findings presented in Chapter 2 
illustrate how Treg cells exert their immunosuppression in the post-transplant setting.  The 
observation that iTreg cells exhibit similar kinetics to suppress GvHD is encouraging, as these 
cells can be expanded to larger numbers ex vivo than is possible with eTreg cells.  However, the 
stability of the iTreg subset remains questionable, and the reversion of these cells to Tcon cells in 
 157 
vivo remains a worrisome possibility.  If these cells are shown to be unstable, co-administration 
with TGF-β, IL-10, or the mTOR inhibitor rapamycin may be able to prevent their de-
differentiation, as well as increase de novo differentiation of inducible Treg cells [27].  Counter-
intuitively, administration of IL-2 may also preferentially support Treg stability and function in 
vivo.  
 In Chapter 4, we showed that claudin-low tumors, one of the intrinsic subtypes of breast 
cancer, demonstrates high immune cell infiltration and utilizes Treg recruitment to suppress the 
anti-tumor response.  The large proportion of infiltrating Treg cells can dominate the immune 
response, preventing the activation and proliferation of CD8+ effector cells.  Even in the absence 
of adoptive effector cell transfer, depletion of Treg cells delays tumor growth, presumably due to 
release of inhibition of effector T cells.   
 Unfortunately, in both of our experiments, Treg depletion cannot be maintained 
throughout the course of the study.  Following two to three rounds of Treg depletion, FoxP3DTR 
(DEREG) mice eventually reconstitute the Treg pool with non-DTR-expressing Treg cells [29].  
Similarly, multiple treatments of low-dose cyclophosphamide cannot be administered, or 
activated and proliferating CD8+ effector T cells will be depleted along with the Treg subset.  This 
is the same mechanism that has limited the utility of CD25-depleting antibodies or IL-2DT 
constructs, as activated effector T cells express the IL-2 receptor along with Treg cells [30].   
 While FoxP3 is specific for Treg cells, it is an intracellular transcription factor and thus 
not targetable by antibody inhibition.  Identification of specific extracellular Treg markers will be 
necessary for the long-term depletion of Treg cells needed for the treatment of solid tumors.  In 
the absence of such a Treg-specific marker, immunotherapy is unlikely to result in curative 
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therapy for the majority of patients treated.  However, lessons learned from the study of GvHD 
can be applied in the tumor setting. 
 Current work suggests that high expression levels of NRP1 is a specific marker for 
endogenous, thymically-derived murine Treg cells, but not inducible Treg cells, and is up-regulated 
on Treg cells from cancer patients [31].  Preliminary data from our laboratory suggest that tumor-
infiltrating Treg cells are eTreg cells, as they express high levels of Helios (unpublished data).  
However, recent studies have shown that Helios is not always a specific marker for eTreg cells, 
leading to an unanswered question of whether tumor-infiltrating Treg cells are endogenous or 
induced [32].  In the event that they are induced, other treatment approaches should target the 
anti-inflammatory signals that lead to their differentiation and function, such as IL-10 and TGF-
β.  Conversely, global depletion of all Treg cells is not without its own side effects.  FoxP3DTR 
(DEREG) adult mice undergoing Treg depletion exhibit adverse symptoms of autoimmunity, 
including hunched posture and fur loss, although it does not reach the levels seen with Treg 
depletion in neonatal mice (unpublished data).  Therefore, the ideal treatment regimen would 
only target those Treg cells in the tumor microenvironment.  
 PD-1 and CTLA-4 inhibitory antibodies are showing great promise in clinical trials for 
many cancers, especially melanoma [33, 34].  Unfortunately, these treatments have shown no 
efficacy thus far in breast cancer [33-35].  One hypothesis for the absence of activity in patients 
with breast cancer is the inclusion of individuals with luminal tumors, which do not generate a 
significant immune response.  Instead, rational use of these drugs would target the smaller 
proportion of breast cancer patients that exhibit heavily Treg-infiltrated tumors, namely triple 
negative breast cancers, or the basal-like and claudin-low intrinsic subtypes.  Indeed, our study 
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showed that depletion of Treg cells with Cy, combined with anti-PD-1 and anti-CTLA-4 antibody 
therapy, significantly delayed tumor growth in a claudin-low breast cancer model.   
 
Effector T Cells 
 Not surprisingly, the treatment benefit observed following Treg depletion and inhibition 
was limited to the minority of mice that endogenously develop a CD8+ T cell response.  Mice 
that failed to develop such a response were incapable of mediating tumor regression following 
therapy.  However, this therapy should not be used in isolation.  Instead, it can and should be 
combined with adoptive cell therapy, where CD8+ effector cells can be activated and expanded 
ex vivo.  Upon return to the patient, these cells can mediate tumor cell killing without the 
immunosuppressive mechanisms that existed during tumor development.   
 The future clinical utility of adoptive cell therapy for solid tumors will be dependent on 
our ability to identify tumor-specific antigens.  Preferably, these would be neo-antigens 
expressed as a result of tumor development, limiting the number of antigen-reactive lymphocytes 
that underwent central deletion during development.  However, even self-antigens that are 
enriched in tumor cells can be targeted.  Unfortunately, there is currently no easy way to identify 
all tumor-associated antigens for a given tumor.  Given the advances made in next generation 
sequencing and bioinformatics, future studies should focus on differences in RNA expression 
between tumor and normal tissue.  The use of RNAseq technology in this setting would help to 
identify antigens that are upregulated on tumor cells or novel antigens resulting from aberrant 
RNA processing or translation. 
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5.3 Concluding Remarks 
 Immunotherapy holds the greatest promise for new and effective therapies in the post-
antibiotic and personalized medicine eras.  Proper balancing of pro- and anti-inflammatory 
signals will require fine-tuning to ensure the scale does not tip too far in either direction.  It is 
also important to remember that these disease processes cannot be studied in isolation, as 
pathways important for the pathogenesis of one disease can be promoted for the treatment of 
another.  Targeted therapy to modify both activating and suppressive pathways will be necessary 
for the control of immune responses desired for proper immunotherapy.  These processes are two 
sides of the same coin, and our ability to tip the balance in whichever direction we choose will 
dictate the effectiveness of new treatments.  While no single pathway is likely to hold the 
solution for any disease, multimodality therapy that targets both sides of the scale promises new 
therapies for the future.
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